

CURRICULUM VITAE

Natasha Kyprianou

Personal Information:

Office Address: Department of Urology
University of Kentucky College of Medicine
800 Rose Street, 306 Combs Building
Lexington, KY 40536-0096

Phone: (859) 323-9812
Fax: (859) 323-1944
Email: nkypr2@uky.edu

Home Address: 5012 Castle Lawn Place
Lexington, KY 40515

Home Phone: (859)-971-1123
Cell Phone: (859) 420-8218

Place of Birth: Paphos, Cyprus

Citizenship: USA

Education:

1977 – 1978 Advanced Level G.C.E. in Chemistry, Physics and Pure Mathematics; London University, London, UK

1978 – 1981 B.Sc. (Honors) in Biochemistry, Queen Mary College, University of London, London, UK

1981 – 1983 M.B. Chemical Pathology, University of Leeds, Leeds, UK

1983 – 1986 Ph.D. in Molecular Endocrinology, University of Wales College of Medicine, Cardiff, S. Wales, UK

Academic Training/Professional Education:

1986 – 1990 Urologic Oncology Fellowship, Department of Urology and the Oncology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

1990 – 1991 Senior Research Fellow, Imperial Cancer Research Fund, London, UK

Present Positions:

2002 – present **James F. Hardymon Chair in Urologic Research**
University of Kentucky Medical Center
Lexington, Kentucky

2002 – present **Professor of Urology, Division of Urology,** Department of Surgery and the Markey Cancer Center, Lexington, Kentucky

2002 – present **Professor of Molecular and Cellular Biochemistry**, Department of Molecular Biochemistry

2003 – present **Professor, Department of Pathology and Laboratory Medicine**
University of Kentucky Medical Center, Lexington, Kentucky

2004 – present **Professor, Graduate Center for Toxicology**
University of Kentucky Graduate School, Lexington, KY

Previous Positions:

1992 – 1998 **Assistant Professor, Department of Surgery, Division of Urology**
University of Maryland School of Medicine, Baltimore, MD

1992 – 1998 **Assistant Professor of Biochemistry and Molecular Biology,**
Department of Biochemistry and Molecular Biology
University of Maryland School of Medicine, Baltimore, Maryland

1992 – 2002 **Director, Urological Research, Division of Urology**
University of Maryland School of Medicine, Baltimore, MD

1998 – 2002 **Associate Professor (with tenure) of Urology and Oncology,**
Department of Surgery, and Greenbaum Cancer Center
University of Maryland School of Medicine, Baltimore, MD

1998 – 2002 **Associate Professor of Biochemistry and Molecular Biology,**
Department of Biochemistry and Molecular Biology
University of Maryland School of Medicine, Baltimore, MD

Awards and Honors:

1983 Doctoral Scholarship, Tenovus Cancer Research, S. Wales, UK

1990 Imperial Cancer Research Fund Fellowship, London, UK

1993 A.F.U.D./A.U.A New Investigator Research Award

1996 A.U.A/CapCURE Contest Winner, AUA Meeting, Orlando, Florida

1996 CapCURE Research Award

1997 Society for Basic Urologic Research Young Investigator Award

1997 Urological Sciences Research Foundation Award for Research Excellence

2002 James F. Hardyman Distinguished Chair in Urology Research

2003 Honorary Kentucky Colonel, Commonwealth of Kentucky

2004 Honorary Member, Board of Directors European Society for Urologic Research

2005 Abraham Flexner Master Educator Award for Outstanding
Teaching/Mentorship, Center for Excellence in Medical Education,
University of Kentucky

2006 Society for Women in Urology/AUA/SBUR Inaugural Award for
Outstanding Contributions to Urology Research

2008 American Urological Association Foundation Distinguished Mentor

- 2009** Dean’s Distinguished Lecture in Clinical and Translational Science, University of Kentucky College of Medicine, “a1-blockade Exploitation Impairs Cancer Metastasis”
- 2009** The Prostate Net, “In the Know” Award for Translational Research/Impact in Prostate Cancer
- 2010-2012** Elected Chair of the U.S. Department of Defense Prostate Cancer Research Program (PCRP) Integration Panel. (PCRP is the second leading source of extramural prostate cancer research funding in U.S.)
- 2010** Dominique Chopin Award in Urology, European Association of Urology/ESUR for Outstanding Contributions to Research and International Scientific Networks
- 2012** Sarah Bennet Holmes Award, Women’s Forum Recognizing Remarkable Women in Commonwealth Kentucky, University of Kentucky
- 2012** University Distinguished Lecturer, Georgia State University, Atlanta, GA
- 2013** Distinguished Mentor Award, Center for Clinical and Translational Science, University of Kentucky
- 2013** Woman of the Year 2012, Academician/Scientist, Cyprus
- 2013** Induction into Johns Hopkins University Society of Scholars
- 2013, 2014** Wethington Award for Academic Excellence, University of Kentucky

Professional Memberships:

- 1990 – 1992** British Association for Cancer Research
- 1991 – present** Society for Basic Urologic Research
- 1992 – present** American Association for Cancer Research
- 1994 – present** New York Academy of Sciences
- 1994 – present** American Association for the Advancement of Science
- 1995 – present** American Urological Association
- 1995 – present** European Society for Urologic Research
- 1996 – present** Society of Women in Urology
- 2003 – present** American Society of Andrology
- 2006 – present** International Cell Death Society
- 2007 – present** British Pharmacological Society
- 2010 – present** Endocrine Society

Academic and Scientific Committees:

- 1993 – 2001** Member, Center for Studies in Reproduction, University of Maryland.
- 1994 – 2001** Member, University of Maryland Graduate School Program
- 1994 – 1996** Member, Membership Committee, Society for Basic Urological Research
- 1994 – 1998** Member, Bressler-Pangborn Awards Committee, University of Maryland School of Medicine Intramural Grants
- 1995 – 1997** Member, University of Maryland Cancer Center Research Committee
- 1995 – 1998** Member, Urological Malignancies Task Force, University of Maryland
- 1997 – 1998** Membership Committee, American Association for Cancer Research
- 1997 – 1999** Member, Awards Committee, Society for Basic Urologic Research
- 1997 – 2001** Member, American Cancer Society Advisory Board, Committee on Molecular Genetics and Oncogenes

1999 – 2000 Member, NIH Operations SBUR subcommittee

1998 – 2001 Ph.D. Thesis Committee Member: Dmitry Grigorev, Thesis Title: “Aromatase Inhibitors for the Treatment of Prostate Cancer”
Thesis Advisor: Dr. Angela Brodie, Professor Department of Pharmacology, University of Maryland School of Medicine, Baltimore

2001 Ph.D. Thesis Committee Member: Karla Sommerville-Amstrong, Thesis Title: “Novel Affinity Reagents for Cross-Linking Human Hemoglobin”; Thesis Advisor: Dr. Ram Hosmane, Professor, Department of Chemistry, University of Maryland Baltimore County, Baltimore

2002 –Present Interviewer, Medical School Admission, University of Kentucky

2003 – 2007 Chair, Thesis Committee for Jason Garrison, IBS Program, Ph.D. Candidate; Thesis title “Novel Quinazolines Targeting Tumor Vascularity”; Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine

2003 – 2010 Ph.D. Thesis Committee Member: Robert Joseph McCorkle, Thesis title: “NM23 in Cancer Cell Metastasis”
Thesis Advisor: Dr. David Kaetzel, Professor, Department of Molecular Pharmacology, University of Kentucky, Lexington

2004 – 2006 Ph.D. Thesis Committee Member: Maria Theodosiou; Thesis title: “Role of the Transcription Coregulator NPDC-1 in Retinoid and Thyroid Receptor Signaling in the Axolotl *Ambystoma Mexicanum*”; Thesis Advisor: Dr. Dan Noonan, Department of Molecular and Cellular Biochemistry, University of Kentucky

2005 – 2006 Ph.D. Thesis Committee Member: Brigham Barber; Thesis title: “Androgen Signaling and the Muscle”; Thesis Advisor: Dr. Karyn Essen, Department of Physiology, University of Kentucky

2006 – 2010 Ph.D. Thesis Committee Member: Yekaterina Zaytseva; Thesis title: “PARR γ Receptor Regulation in Breast Cancer”; Thesis Advisor: Dr. Michael Kilgore, Department of Pharmacology, University of Kentucky

2006 – 2012 Ph.D. Thesis Committee Member: Marian Novak; Thesis title: “Metastasis Suppressor Gene NM23 in Melanoma”; Thesis Advisor: Dr. David Kaetzel, Department of Pharmacology, University of Kentucky

2007 Chair, Surgery Research Grant Review Committee, University of Kentucky

2007 – 2010 Ph.D. Thesis Committee Member: Perry Christian; “Antigen-Induced Cell Death and Proteasome Inhibition, A Synergistic Cancer Therapy;” Thesis Advisor: Dr. Steven Schwarze, Department of Molecular Biochemistry

2007 Molecular Oncology Faculty Search Committee, Markey Cancer Center, University of Kentucky

2008 – 2012 Ph.D. Thesis Committee: Michael Fiandalo; “Proteasomal Regulation of Caspase-8 in Apoptosis Signaling”; Thesis Advisor: Dr. Natasha Kyprianou, Department of Molecular Biochemistry

2009 Molecular and Biomedical Pharmacology Departmental Review Committee, University of Kentucky College of Medicine

- 2009 – 2010** Ph.D. Thesis Committee Examinnerr: Madan Kharel; Thesis title: “Dissecting the Biosynthesis of Gilvocarin and Ravidomycin”; Thesis Advisor: Dr. Jurgen Rhor, Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky
- 2009 – 2014** Ph.D. Thesis Committee Chair: Joanne Collazo; “Regulation of Cytoskeleton and Actin Organization by TGF-β in Prostate Cancer”; Department of Toxicology, University of Kentucky
- 2010 –** Ph.D. Thesis Committee Member: Daniel Ledbetter; “Molecular Characterization of Bcl-2 Transgenic Mice: Significance in Human Disease”; Thesis Advisor: Dr. Edmund Rucker, Department of Biology, University of Kentucky
- 2011 –** Ph.D. Thesis Committee Member: Chris Stamatkin; “Novel Therapeutics Targeting Lung Cancer”; Thesis Advisor: Dr. Penni Black, Department of Pharmaceutical Sciences, University of Kentucky
- 2011 –** Ph.D. Thesis Committee Chair: Emily Matuszak; “Regulation of Epithelial-Mesenchymal Transition (EMT) in Prostate Cancer Progression to Metastasis”; Department of Toxicology, University of Kentucky
- 2011 –** Ph.D. Thesis Committee Chair: Sarah Martin; “Mechanisms of Taxane Resistance in Castration Resistant Prostate Cancer”; Department of Biochemistry, University of Kentucky
- 2011 – 2014** External Advisory Board Member, Prostate Cancer Biorepository Network (PCBN), Department of Defense
- 2013** Ph.D. Thesis Committee Examiner: Sandra Barnard; Thesis title: “Amalgamation of Nucleosides and Amino Acids in Capuramycin-Related Antibiotic Biosynthesis”; Thesis Advisor: Dr. Steven Van Lanen, Department of Pharmaceutical Sciences, University of Kentucky

Other Significant Scholarly, Research or Administrative Experience:

- 1992 – 2001** **Director, Resident Research Program, Division of Urology** University of Maryland Medical System, Baltimore, MD
- 1993 – 1996** **Research Mentor to General Surgery Residents,** Department of Surgery University of Maryland Medical System Baltimore, Maryland
- 2002 – 2006** **Associate Director of Research,** Department of Surgery University of Kentucky Medical Center, Lexington, KY
- 2004 – present** **Graduate Faculty,** Molecular and Cellular Biochemistry Program, University of Kentucky, Lexington, Kentucky
- 2004 – 2005** **Member,** CAART Committee, Markey Cancer Center, University of Kentucky
- 2006 – 2008** **Member,** Strategic Planning Committee for Prostate Clinical/Basic Science, NIDDK/NIH
- 2006 – 2007** **Member,** IMPaCT Meeting Organizing Committee, “Innovative Minds in Prostate Cancer Today,” Department of Defense, PCRP Program
- 2006 – Present** **Member,** Programmatic Committee Integration Panel, Department of Defense, Prostate Cancer Congressionally Directed Research Program

2007 – Present **Team Leader**, Abstract Review for Prostate Cancer Basic Science, American Urological Association (AUA) Annual Meeting

2009 – Present **Member**, External Advisory Committee, Research Training Program in Urology (PI: Dolores Lamb, Ph.D.); Department of Urology, Baylor College of Medicine, Houston, TX

2008 –2013 **Reviewer**; Markey Cancer Center Project Reviews, UK

2010 – Present **Member**; NIH College of CSR Reviewers

2010 – 2014 **Member**; AUA Urology Care Foundation Research Council

2011 – Present **Associate Board Member**, European Society for Urologic Research

2012 – **Member**, Stand Up to Cancer (SU2C) Scientific Advisory Committee, American Association for Cancer Research (AACR)

2014 – Member, External Advisory Board, GU Oncology Program, Roswell Park Cancer Institute, Buffalo, NY

2014 – **Member**, External Advisory Board, PPG Hollings Cancer Center, Medical University of South Carolina, Charleston, S.C.

2014 – **Board Member**, Irish Cancer Society, Dublin, Ireland

Teaching Experience:

1993 – 2000 Conference Leader, Medical Biochemistry Course, Medical Student Teaching Program, Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine

1994 – 2001 Lecturer, Molecular Biology and Advanced Molecular Biology Courses, Graduate Program, Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine

1996 – 1999 Lecturer, Biology of Cancer Course, Department of Pathology, University of Maryland School of Medicine

1997 – 1999 Course Director and Lecturer, FAES Workshop on “Apoptosis in Normal Homeostasis and Disease Development and Treatment” NIH, Bethesda

2000 – 2002 Lecturer, Cell and Molecular Biology Course, First Year Medical Students, University of Maryland School of Medicine, Baltimore

2003 – 2010 Lecturer, Biochemistry Course (401), Undergraduate Students, University of Kentucky, Lexington

2003 – 2011 Course Instructor/Lecturer, Cancer Cell Signaling, Cell Biology and Signaling Course (IBS 603); University of Kentucky College of Medicine

2004 – Present Lecturer, Cancer Biology Course, IBS Graduate Program (IBS 616), University of Kentucky College of Medicine, Lexington

2004 – 2011 Lecturer, Molecular Epidemiology and Cancer Prevention Class; SPH718, Markey Cancer Center, University of Kentucky, Lexington

2007 CRS Seminar presentation, “Targeting apoptotic pathways in treating prostate cancer”, University of Kentucky, November 2007

2008- 2011 Lecturer, Mechanisms of Human Diseases, PGY 630-020, Physiology Department, University of Kentucky

2008-2012 Lecturer, Hematology/Oncology Fellowship Forum, Markey Cancer Center, University of Kentucky

2009-2014 Lecturer in Cancer Biology and Cell Signaling, Molecular Biology Class, Asbury College, Wilmore, KY

2014- Organizer/Lecturer Workshop on Biology of Cancer, Universidad Central del Caribe, Puerto Rico, PR

Study Section Activities/Peer Review Panel Membership:

1992 Member, Special Review Panel for Specialized Programs of Research Excellence (SPORE) in Prostate Cancer, National Cancer Institute, NIH, Bethesda, MD.

1995 – 1999 Member, Review Committee, University of Maryland Cancer Center Research Grants

1996 – 2004 Ad Hoc Reviewer, General Medicine Study Section, Urology Special Emphasis Panel (SEP), NIH

1997 – 2002 Ad Hoc Reviewer, Oncology Merit Review Board, VA Medical Research

1997 – 2004 Research Grants Review Committee Member, American Foundation for Urologic Disease

1997 – 2000 Review Committee, Medical Research Council, Clinical Research Awards, UK.

1997 – 2001 Member, Advisory Committee on Molecular Genetics and Oncogenes, American Cancer Society

1998 – 2004 Member, Peer Review Committee, Cell Biology; Department of Defense Prostate Cancer Program, U.S. Army Medical Research and Materiel Command

1998 – 2003 Member, Peer Review Committee; Department of Defense Breast Cancer Program, U.S. Army Medical Research and Materiel Command

1999 Review Committee, George O'Brien Centers in Urology, NIDDK

2000 – 2002 Member, Peer Review Committee (Cell Biology), California Cancer Research Program, San Francisco, CA

2000 Ad Hoc Reviewer, New Jersey Cancer Research Program

2000 Reviewer, National Cancer Institute Program Project Review/Site Visit; Memorial Sloan Kettering Cancer Center, New York

2000 Member, NIDDK-D RFA Special Grants Review Committee, Bethesda

2001 Member, Peer Review Committee, Molecular Biology Section, Department of Defense Prostate Cancer Program, U.S. Army Medical Research and Materiel Command, Washington, D.C.

2000 – 2001 Reviewer, National Cancer Institute (NCI), Program Project on Bladder Cancer Molecular Markers, Memorial Sloan Kettering Cancer Center, Site Visit, PI: Dr. Carlos Gordon-Cardo, New York

2002 Adhoc, Cancer Molecular Pathobiology Study Section (CAMP), NIH

2002 Ad Hoc Reviewer, Endocrinology and Reproductive Sciences Study Section, NIH, Bethesda, MD

2002 Reviewer, National Cancer Institute (NCI), Program Project on Bladder Cancer, Site Visit, USC Cancer Center, PI: Dr. Peter Jones

2002 – 2003 Reviewer, Cardura Competitive Research Awards, Pfizer, New York

2003 Co-Chair/Member, Peer Review Committee, George O'Brien Centers in Urology, Washington, D.C., NIH/NIDDK

2003 Adhoc Member, Parent Subcommittee D-Clinical Studies, NCI Review, NCI/NIH, Bethesda, MD

2003 Adhoc Reviewer, RFA “Molecular Targets for Nutrients in Prostate Cancer Prevention”, NIH/NCI, Bethesda, MD

2003 Reviewer, Prostate Cancer Program, Irish Cancer Society

2003 – 2004 Reviewer, National Cancer Institute Site Visit, Program Project on “Apoptosis-Based Immunotherapy for Prostate Cancer”; PI: Dr. John Reed, The Burnham Institute, La Jolla, California.

2003–2008 Chartered Member, Cancer Molecular Pathobiology Study Section (CAMP), NIH, Washington, D.C.

2004 Adhoc Member, Urologic and Kidney Development & Genitourinary Diseases Study Section, Washington, D.C.

2004 Chair, Grant Review Panel, Cell Biology-4, Breast Cancer Program, U.S. Department of Defense, Arlington, VA

2004 – 2006 Member, Program Projects Cluster Review Panel; NCI Subcommittees, D and E; Washington D.C.

2004 – 2007 Chartered Member, Parent Subcommittee-C, Basic and Preclinical Review Group, National Cancer Institute, NIH, Bethesda, MD

2006-2009 Member/Discussion Leader, Discovery and Development P01 Special Emphasis Review Panel, NCI, SRA: Dr. Peter Wirth, Washington, DC

2006 Chair, IMPaCT (Innovative Minds in Prostate Cancer Today) Abstract Committee Meeting, SAIC, Congressionally Directed Medical Research Programs, April 2006, Washington, DC

2006 Reviewer, Irish Clinical Research Grants

2007 Chair, Cell Biology Review Panel, Department of Defense Breast Cancer Research Program

2007-2008 Reviewer, Medical Research Council, Ministry of Health, Singapore

2007-2010 American Urological Association Research Foundation Scholarships

2008 External Reviewer, Michael Smith Foundation, Vancouver, British Columbia.

2008 Reviewer, Science Foundation Ireland, Dublin, Ireland

2008 Acting Chair, George O’Brien Urology Research Centers (P50 Program) Reviews, NIH/NIDDK

2008 Reviewer, Prostate Cancer Foundation of Australia, Melbourne, Australia

2008 Reviewer, Academy of Sciences of the Czech Republic, Prague

2009 Review Panel Member, Cancer Therapeutics Discovery and Development Treatment SBIR/STTR Study Section, CSR/NIH, Bethesda, MD

2009 Pre-Doctoral Diversity Fellowships Review Panel, NIH, Washington DC

2009 Reviewer, Swiss National Science Foundation, Zurich, Switzerland

2009 Member, Distinguished Editorial Panel, NIH Challenge Grants

2009 Ad Hoc Reviewer VA Oncology Committee Merit Reviews

2009 Ad Hoc Reviewer, Molecular Oncogenesis Study Section, CSR/NIH

2009-2011 Reviewer, Prostate Cancer Charity Research Awards, London, UK

2009-2011 Chair-elect of the U.S. Department of Defense Prostate Cancer Research Program (PCRP) Integration Panel.

2010 AdHoc Reviewer, Molecular Mechanisms of Cancer Therapeutics Study Section, CSR/NIH. Washington DC

2010 Reviewer, Small Business Grants (SBIR/STTR), Cancer Treatment and Diagnosis

2010 Member, Distinguished Editorial Panel, NCI, Director's Opportunity for Translational Clinical Oncology
2010 Oncology I-Basic Translational Integrated Review Group, CSR/NIH
2010 Reviewer, Drug Discovery and Development P01 Review Panel, NIH/NCI, Bethesda, MD
2010 Reviewer, Special Emphasis Panel, Normal and Oncogenic Signal Transduction Pathways (Teleconference), NIH
2011 Member, Discovery/Imaging Therapeutics NCI Program Projects P01 Review Panel, NIH, Bethesda, MD
2011-2012 Member, Special Emphasis Panel on Cancer Health Disparities and Diversity in Basic Cancer Research, NCI/NIH, Washington DC
2011- Reviewer, Irish Cancer Society Prostate Cancer Research Programs
2011-2013 Member, PCRP External Advisory Board, Prostate Biorepository Network
2011 Reviewer, Special Emphasis Panel, Oncology: Basic Translational, NIH
2011 Reviewer, Cancer Diagnostics & Treatment, Special Emphasis Panel, NIH
2011 Reviewer, Austrian Science Foundation
2011 Co-Chair, Cancer Drug Development Study Section, Oncology 2-Translational Clinical, NIH, Bethesda, MD
2011-2012 Member, Stand Up to Cancer (SU2C)-American Association for Cancer Research (AACR); Prostate Cancer Foundation (PCF) Joint Scientific Advisory Committee (JSAC)
2012- Present Member/Discussion Leader, Program Projects P01 Special Emphasis Panel, NCI/NIH, Bethesda, MD
2012-2015 Reviewer, Lasker Clinical Research Scholars Program, NIH
2012-2013 Member, Prostate Cancer Foundation (PCF) Challenge Awards Review Committee, Santa Monica, CA
2012 Reviewer, Cancer Research Grants, Portuguese Foundation for Science and Technology
2012 Reviewer, PCF Australia Research Program and Training Grants
2012 Member Reviewer, 2012 AACR-Kure It Grant for Kidney Cancer Research
2012 Comision Nacional de Investigacion, National Fund for Scientific and Technological Research, (FONDECYT) Program, Chile
2013 AdHoc Reviewer, Cancer Etiology Study Section, NIH
2013 Reviewer, SEP Panel, SPORC Programs, NCI/NIH, Bethesda, MD
2013 Member, NCI Grant Review Panel on Provocative Questions, NIH
2013-Present Reviewer, Medical Research Council, UK
2013-Present Reviewer, Prostate Cancer Research UK
2013-Present Reviewer, Special Emphasis Panel, Therapeutics Discovery and Development, OMNIBUS, NCI Washington, DC
2014 Reviewer, Special Emphasis Panel on Biomarkers Using Biosamples from NIDDK Repository, NIH (Teleconference)
2014 Reviewer, Austrian Science Foundation
2014 Reviewer, National Bladder Cancer Research Network Innovation Award
2014 AdHoc Reviewer, Developmental Therapeutics Study Section (DT), NCI/NIH

- 2014 –** AdHoc Reviewer, NIH/NCI Basic Mechanisms of Cancer Therapeutics Study Section (BMCT), Chicago, IL
- 2014 – 2016** Member, AACR Basic Cancer Research Fellowships Scientific Review Committee

Consulting Activities:

- 1997 – 2003** Consultant, Pfizer Pharmaceuticals (Doxazosin Clinical Program)

Elected Officer:

- 2003 – 2005** President, Society for Basic Urologic Research (SBUR)
- 2009 – 2012** Chair of the U.S. Department of Defense Prostate Cancer Research Program (PCRP) Integration Panel

Conference Organizer:

- 1999 – 2000** Organizing Committee, SBUR 2000 Fall Symposium on Prostate Cancer
- 2000 – 2001** Conference Chair, SBUR Fall 2001 Meeting/World Congress in Urologic Research, Tucson, Arizona
- 2001 – 2002** Member, Advisory Board, 2002 International Symposium in Prostate Cancer, Baltimore MD
- 2001 – 2002** Organizing Committee, SBUR Fall 2002 Symposium, Tucson, AZ
- 2002 – 2003** Member, Organizing Committee, Fifth World Congress in Urologic Research, London, UK
- 2003 – 2004** Organizing Committee, SBUR Fall 2004 Meeting, Savannah, GA
- 2004** Organizer, SBUR Symposium, ESUR 2004 Congress, Athens, Greece
- 2004 – 2005** Member, Program Organizing Committee, AUA 2005 Meeting, San Antonio, TX
- 2005** Member, Organizing Committee, NPG Symposium in Uro pharmacology/ SBUR Fall 2005 Meeting, Miami Beach, FL
- 2005 – 2006** Member, Program Organizing Committee, AUA 2006 Meeting, Atlanta, GA
- 2005 – 2006** Member, Organizing Committee, SBUR Spring 2006 Meeting, Atlanta, GA
- 2006 – 2007** Chair, IMPaCT (Innovative Minds in Prostate Cancer Today) Organizing/ Abstract Committee, SAIC (Science Applications International), Congressionally Directed Medical Research Programs
- 2010 – 2011** Co-Chair, IMPaCT (Innovative Minds in Prostate Cancer Today) Meeting, Department of Defense/Congressionally Directed Medical Research Programs, Orlando, FL
- 2011 – 2012** Co-Chair, AUA Summer Research Conference, “Hormonal Therapies in Urologic Disease”, Lithicum, MD
- 2012 – 2013** Organizer/Chair/Speaker, 1st Anticancer Symposium/4th International Conference on Recent Advances in Health and Medical Sciences, Pafos, Cyprus

Board Memberships:

- 1999 – 2001** Member, Executive Board, Society for Basic Urologic Research
- 2001- Present** Board Member, International Prostate Health Council
- 2004 - 2009** Member, American Urological Association Education Council
- 2010 - 2014** Member, American Urological Association Foundation Research Council

2014 – Member, Board of Directors, Irish Cancer Society

Editorial Boards:

2000–Present Associate Editor, *The Prostate*
2005–Present Associate Editor, *Cancer Research*
2006–2009 Associate Editor, *British Journal of Pharmacology*
2007–2011 Associate Editor, *AUA News*
2008–2013 Editorial Board, *The Open Prostate Cancer Journal*
2010–Present Senior Academic Editor, *PLOS ONE*
2012–Present Associate Editor, *APOPTOSIS*
2013–Present Associate Editor, *Molecular Cancer Research*
2013–Present Associate Editor, *Journal of Experimental and Clinical Urology*
2014– Associate Editor, *ENDOCRINOLOGY*
2014– Associate Editor, *Asian Journal of Urology*
2014– Editorial Board, *Biomedicine and Pharmacotherapy*

Editorial Consultant/Reviewer:

American Journal of Pathology
Apoptosis
Archives of Pharmacology
Asian Journal of Andrology
British Journal of Pharmacology
Biochimica Biophysica Acta; BBA Molecular Cell Research
BBA Molecular Basis of Disease
BBA Molecular Cell Research
British Journal of Cancer
British Journal of Medicine and Medical Research
British Journal of Urology
British Journal of Urology International
Canadian Journal of Physiology and Pharmacology
Cancer
Cancer Biology and Therapy
Cancer Cell International
Cancer Research
Cancer Chemotherapy and Pharmacology
Cancer Detection and Prevention
Cancer Gene Therapy
Cancer Letters
Carcinogenesis
Cell Cycle
Cell Death and Differentiation
Cell Death and Disease
Cell Proliferation
Cellular and Molecular Life Sciences
Clinical Cancer Research
Clinical and Translational Medicine

Drug Discovery Today
EMBO Molecular Medicine
EMBO Reports
Endocrinology
Endocrine-Related Cancer
European Journal of Cancer Genetics
European Journal of Endocrinology
European Journal of Medicinal Chemistry
European Urology
Experimental Cell Research
Expert Opinion on Emerging Drugs
Expert Opinion on Therapeutic Targets
FEBS Letters
Female Pelvic Medicine & Reconstructive Surgery
Future Medicine
Genes & Cancer
Gene Therapy and Molecular Biology
Journal of Andrology
Journal of Cancer
Journal of Cell Science
Journal of Cellular Biochemistry
Journal of Clinical Investigation
Journal of Clinical Endocrinology and Metabolism
Journal of Endocrinology
Journal of Experimental Medicine
Journal of Histochemistry and Cytochemistry
Journal of Medicinal Chemistry
Journal of Molecular and Cellular Medicine
Journal of National Cancer Institute
Journal of Steroid Biochemistry
Journal of Steroid Biochemistry and Molecular Biology
Journal of Translational Medicine
Journal of Urology
Integrative Biology
International Journal of Andrology
International Journal of Cancer
International Journal of Experimental Pathology
International Journal of Medical Sciences
International Journal of Radiation Biology
IUBMB Life
International Urology and Nephrology
Key Opinions on Cancer Therapy
Key Opinions in Molecular Medicine
Laboratory Investigation
Life Sciences
Metabolomics

Mini Reviews in Medicinal Chemistry
Molecular Biology of the Cell
Molecular Cancer
Molecular Cancer Research
Molecular Cancer Therapeutics
Molecular Carcinogenesis
Molecular and Cellular Biochemistry
Molecular Endocrinology
Molecular Oncology
Nature
Nature Communications
Nature Reviews Cancer
Neoplasia
Nanoscale
Pathology-Research and Practice
Proceedings of National Academy of Science (PNAS)
Oncogene
Oncology Research
Oncotarget
The Prostate
Tumor Biology
Prostate Cancer and Prostatic Diseases
Reuters' Drug Profiles
Science
Science Signaling
Science Translational Medicine
Stem Cell Research
Systems Biology in Reproductive Medicine
Theranostics
Tissue and Cell Research
Urology
World Journal of Urology

Research Support:

Active:

NIH/NIDDK 2 R01 GRANT00491815

Principal Investigator: **Kyprianou, Natasha** 25% effort

“Novel Effectors of TGF- β Signaling in Prostate Growth Regulation and Tumor Progression”

7/1/10-6/30/15

Direct Costs: \$250,000/year

Sanofi-Aventis Investigator-Initiated Jevtana Pre-Clinical Concept

Principal Investigator: **Kyprianou, Natasha**

Pre-clinical Evaluation of Cabazitaxel Mechanisms in Prostate Cancer Therapy

5/1/13-7/31/2015

Direct Costs: \$165,800/year

NIH/NIEHS T-32 ES07266
PI: Mary Vore Mentor: **Kyprianou, Natasha**
“Training Grant in Molecular Mechanisms of Toxicity”
7/1/10-6/30/15

NIH 1S10RR029127-01
PI: Haining Zhu Other/Major User: **Kyprianou, Natasha**
“LTQ Orbitrap XL ETD mass spectrometer”
2010-2015

NIH T32CA160003
PI: Mark Evers Mentor: **Kyprianou, Natasha**
Oncology Research Training for Surgeon-Scientists”,
Goal: To train the next generation of surgeon-scientists in the
multidisciplinary aspects of cancer research
2011-2016

NIH 1K08CA155764-01
PI: Craig Horbinski Mentor: **Kyprianou, Natasha**
“The Significance of Isocitrate Dehydrogenase Mutations in Glioma”
2011-2016

Pending:

NIH/NCI
Principal Investigator: **Kyprianou, Natasha** 25% effort
EMT Control in Prostate Cancer Progression
11/1/14-10/31/19 Direct Costs \$250,000/year

NIH/NCI
Principal Investigator: **Kyprianou, Natasha** 20% effort
Overcoming Resistance to Anti-Androgens and Taxanes in Prostate Cancer
12/1/2014-1/30/19 Direct Costs: \$250,000/year

Movember-PCF Global Treatment Sciences Network Challenge Award
Principal Investigator Channing Paller (Johns Hopkins Medical Institutions)
Co-Investigator: **Kyprianou, Natasha** (10%)
Overcoming resistance to enzalutamide with first-in-class TGF- β inhibition
12/1/14-9/30/16 Direct Costs: \$100,000/year

Completed:

Department of Defense W81XWH-08-1-0431
Congressionally Directed Prostate Cancer Programs Synergistic Development Award:
Co-Investigator: **Kyprianou, Natasha (10% effort)**; Partnering Co-Investigator, Haining Zhu;
Project Title: “Biomarker Discovery in Prostate Cancer Using Targeted Proteomic Approaches”
2008-2012

NIH RR-03-014
Centers for Biomedical Research Excellence (COBRE)
PI: Hersh, Louis 10% effort
Project 5: "Dissecting the Cell Surface Proteome of Prostate Cancer"
Project leader: Zhu, Haining; Co-Principal Investigator (5% effort): **Kyprianou, Natasha**
9/04-7/10 Direct Costs \$1,371,188/year

Patents and Inventions:

US Patent and Trademark Office (USTPTO) University of Kentucky/Ohio State University Joint Invention, U.S. Patent Application S.N. 12/323,073. Co-inventors: Chen, C., Garrison, J., Shaw, J.S. "Novel Antitumor Agents and Methods of their Use in Targeting Prostate Cancer"

Mentoring:

Faculty:

1997 – 2000 Toby Chai, M.D., Professor of Urology/Surgery,
University of Maryland Medical Center, Baltimore, MD
2003 – 2006 Haining Zhu, Ph.D., Associate Professor of Molecular and Cellular
Biochemistry, University of Kentucky, Lexington, KY
2005 – 2011 Steven Schwarze, Ph.D., Assistant Professor of Molecular and Cellular
Biochemistry, University of Kentucky, Lexington, KY
2006 – 2008 Vernon Pais, M.D., Assistant Professor of Urology, Department of
Surgery, University of Kentucky, Lexington, KY
2006 – 2008 Kyung-Bo Kim, Ph.D., Assistant Professor of Pharmaceutical Sciences,
University of Kentucky, Lexington
2007 – 2012 Andrew Bernard, M.D., Assistant Professor of Surgery, Department of
Surgery, University of Kentucky, Lexington, KY
2009 – Present Craig Horbinski, MD, Ph.D., Assistant Professor of Pathology,
Department of Pathology, University of Kentucky, KY
2010 – 2013 Qing-Bai She, Ph.D., Department of Molecular Biochemistry and Markey
Cancer Center, University of Kentucky, KY

Residents:

1992 – 1993 Geoffrey Sklar, M.D., Urology Resident
Current Position: Urology Director, Maryland Urology Associates
Glenn Burnie, Baltimore, MD
1992 – 1993 Tracy Burney, M.D., Urology Resident
Current Position: Attending Urologist, University of Florida, Orlando
1993 Shammai Rockove, M.D., Urology Resident
Current Position: Urologist, University of Oregon Health Sciences, OR
1993 – 1994 Ronald Benoit, M.D., Urology Resident
Current Position: Assistant Professor of Urology
University of Pittsburgh, Pittsburgh, PA
1993 – 1994 Walter Sartor, M.D., Surgery Resident
Current Position: Attending Surgeon, Monroe, LA
1994 – 1995 Edward King, M.D., Urology Resident

Current Position: Urology Attending, Orlando, FL
1994 – 1995 Derrick Burno, M.D., Resident
 Current Position: Private Practice Urologist, New Jersey
1995 – 1996 Steven Rock, M.D., Urology Resident
 Current Position: Urology Attending/Private Practice, MD
1995 – 1996 Juan Montogia, M.D., Surgery Resident
 Current Position: Urology Attending, Houston, TX
1996 – 1997 Jennifer Berman, M.D., Urology Resident
 Current Position: Director of Female Sexual Medicine Clinic/Women LA
 Insititute/UCLA, Los Angeles, CA
1996 – 1997 Timothy Mackey, M.D., Urology Resident
 Current Position: Urology Attending, New Jersey
1997 – 1998 David Sigman, M.D., Urology Resident
 Current Position: Assistant Professor of Urology
 Sinai Medical Center, Baltimore, MD
1997 – 1998 Joanna Chon, M.D., Urology Resident
 Current Position: Urology Private Pracice, Orlando, FL
1998 – 1999 Joseph Del Pizzo, M.D., Urology Resident
 Current Position: Associate Professor of Urology/Director of
 Endourology, Cornell Medical School, New York, NY
1998 – 1999 Deborah Glassman, M.D., Urology Resident
 Current Position: Associate Professor of Urology
 Thomas Jefferson University, Philadelphia, PA
1999 – 2000 Michael Szostak, M.D., Urology Resident
 Current Position: Urologist, West Palm Beach, Florida
2000 – 2001 David Cuellar, M.D., Urology Resident
 Current Position: Attending Urologist, Dallas, TX
2001 – 2002 Brian Hill, M.D., Urology Resident
 Current Position: Attending Urologist, Atlanta, GA
2004 – 2005 Shaun McKenzie, M.D., Surgery Resident
 Current Position: Assistant Professor, Department of Surgery, University
 of Texas, Austin, TX
2005 – 2008 Francis Martin, M.D. Urology Resident, University of Kentucky
 Current Position: Urologist, Lakeland, FL
2006 – 2009 Bradley Warner M.D., Urology Resident, University of Kentucky
 Current Position: Attending Urologist, Portland, OR
2008 – 2011 Renee Quillin, MD. Urology Resident, University of Kentucky Medical
 Center, Lexington, KY
 Current Position: Urologist, Tampa, FL
2012 – 2014 Lauren Hendrix M.D., Urology Resident, University of Kentucky, KY
2013 – Present John Lacy, M.D., Urology Resident, University of Kentucky, Medical
 Center, KY
2013 – Present Barbara Khan, M.D., Urology Resident, University of Kentucky, KY
2014- Jonathan Walker, Urology Resident, University of Kentucky, KY

Postdoctoral Fellows:

1992 – 1995	Huacheng Tu, M.D., Postdoctoral Fellow
1992 – 1994	Neena Bains, M.D., Postdoctoral Fellow
1999 – 2001	Elizabeth Bruckheimer, Ph.D. (AFUD Scholar, 2000-2002), Current Position: Associate Director, Systems Medicine LLC, Phoenix, AZ
1999 – 2001	Kaspar Keledjian, M.D., Postdoctoral Fellow
2000 – 2002	Ian Anglin, Ph.D., Postdoctoral Fellow Current Position: Scientist, Institute of Virology, University of Maryland
2002 – 2003	Li Zeng, M.D., Ph.D., Visiting Scientist, Associate Professor of Pathology; University of Beijing Urologic Institute
2002 – 2003	Ash Vyas, M.D., Postdoctoral Fellow
2003 – 2004	Anastasios Tahmatzopoulos, M.D., Postdoctoral Fellow Current Position: Assistant Professor, Aristotelion University, Thessaloniki, Greece
2004 – 2006	Gabriella Rennebeck, Ph.D., Postdoctoral Fellow Lecturer- University of San Antonio, Texas
2004 – 2009	Brian Zhu, M.D., Ph.D., Postdoctoral Fellow Current Position: Research Assistant Professor, University of Kentucky Center for Diabetes and Obesity
2006 – 2009	Shinichi Sakamoto, M.D., Ph.D., Postdoctoral Research Fellow Current Position: Associate Professor, Department of Urology, Chiba University, Tokyo, Japan
2006 – present	Hong Pu, M.D., Staff Scientist I
2010 – 2011	Andreas Desiniotis, Postdoctoral Research Fellow
2014 –	Zheng (Zack) Cao, Post-doctoral Fellow

Graduate Students:

1994 – 1998	Yanping Guo, Graduate Student, Ph.D. Program, Department of Biochemistry and Molecular Biology, University of Maryland Medicine
1994 – 1995	Rebecca Caldwell, Master's Program
1995 – 1996	David Bradbury, Master's Program
1996	Debra Stucker, Graduate Student (Rotation)
1998	Jingsong Zhu, Graduate Student (Rotation)
1999 – 2003	Rachel Winter, Ph.D. Program, Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine
2003 – 2007	Jason Garrison, IBS Program, Ph.D. Candidate, Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine
2004 – 2005	Menglei Zhu, Graduate Student, Graduate Program in Toxicology (Rotation)
2005	Enerlyn Lozada, Graduate Program in Toxicology (Rotation)
2005	William Velez, IBS Graduate Program, University of Kentucky (Rotation)
2005	Ekaterina Zaytseva, IBS Graduate Program (Rotation)
2006	Shi Ping, Graduate Program in Toxicology (Rotation)
2006	Andreea Popa, IBS Graduate Program (Rotation)
2006 – 2007	Brynn Rybak, IBS Graduate Program, Ph.D. Candidate, Department of Molecular and Cellular Biochemistry, University of Kentucky
2007	Michael Opata, IBS Graduate Program (Rotation)

2006 – 2007	William Velez, IBS Graduate Program, M.Sc. Candidate, Department of Molecular and Cellular Biochemistry, University of Kentucky
2007 – 2010	Meng Lei Zhu, Toxicology Graduate Program, Ph.D. Graduate Center for Toxicology, University of Kentucky College of Medicine
2007 – 2008 2008	Gang Wang, Ph.D. Candidate, University of British Columbia, Examiner Yuqian Zhang, Department of Molecular and Cellular Biochemistry, University of Kentucky, Seminar Advisor.
2008 – 2014	Joanne Collazo, Toxicology Graduate Program, Ph.D. , Graduate Center for Toxicology, UK College of Medicine Current Position: Assistant Professor, School of Science and Technology at Ana G. Mendez University System, Puerto Rico
2010 – 2012	Emily Matuszak, Toxicology Graduate Program, M.Sc. Graduate Center for Toxicology, UK College of Medicine
2011 – present	Sarah Martin, IBS Program, Ph.D. Candidate, Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine
2010 – 2012	Michael Fiandalo, Ph.D. Candidate, Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine Current Position: Post-doctoral Fellow, Department of Urologic Oncology, Roswell Park Cancer Institute, Buffalo, NY
2011	Matthew Thacker, IBS Graduate Program, Rotation Student
2011 – 2012	Murli Mishra, Graduate Program in Toxicology, University of Kentucky College of Medicine, Rotation Student
2013	Maria Dixon, IBS Graduate Program, Department of Biochemistry, University of Kentucky, Rotation Student
2013	Khalid Eldahan, IBS Graduate Program, Department of Molecular and Cellular Biochemistry, University of Kentucky, Rotation Student
2014	Marisa Kamelgarn, IBS Graduate Program, Department of Molecular and Cellular Biochemistry, Rotation Student

Medical Students:

1994	James Matteson, University of Maryland School of Medicine
1995	Michael Franks, University of Maryland School of Medicine
1996 – 1997	Juan Litvak, University of Maryland School of Medicine
1998	Priti Kaur, University of Maryland School of Medicine
1998 – 1999	Andrew Kramer, University of Maryland School of Medicine
2000 – 2001	Grace Kim, University of Maryland School of Medicine (M.D./Ph.D.)
2003	Kuwong Mwamukonda, University of Kentucky College of Medicine
2003 – 2004	Aaron Becker, University of Kentucky College of Medicine
2004 – 2005	Jason Bylund, University of Kentucky College of Medicine
2005 – 2007	Andrew Harris, University of Kentucky College of Medicine
2005	Daniel S. Bramer, University of Kentucky College of Medicine
2005	John Williams, University of Kentucky College of Medicine
2005	Jeffrey Nix, University of Kentucky College of Medicine
2006	Jamie Messer, University of Kentucky College of Medicine
2006	Adam Vogt, University of Kentucky College of Medicine
2006	Justin Dixon, University of Kentucky College of Medicine

2007	Garret Korret, University of Kentucky College of Medicine
2007 – 2009	Ryan Reynolds, University of Virginia School of Medicine
2007	Justin Johnson, University of Kentucky College of Medicine
2007 – 2008	Dustin Gayheart, University of Kentucky College of Medicine
2008	John-Paul Scopetta, UK College of Medicine
2009	Taylor Vaughan, University of Kentucky College of Medicine
2009	Elisabeth Jones, University of Kentucky College of Medicine
2010	Matthew Mart, University of Kentucky College of Medicine
2010	Timothy Atkinson, University of Kentucky College of Medicine
2010 – 2015	Patrick Hensley, University of Kentucky College of Medicine
2012 – 2015	Spencer Larkin, University of Kentucky College of Medicine
2013 – 2014	Campbell Grant, University of Kentucky College of Medicine
2014 – 2015	Jahan Miremami, University of Kentucky College of Medicine
2014-	Timothy Stark, University of Kentucky College of Medicine
2014-	Justin Penticuff, University of Kentucky College of Medicine

Undergraduate Students:

2001	Kokab Bargandi, University of Maryland, Baltimore, MD
2002	Melissa Yingling, University of Virginia, Charlottesville, VA
2003	M. Tandy Suttton, Transylvania University, Lexington, KY
2004	Joel Carter, University of Kentucky, Lexington, KY
2004	Matthew Martelli, University of South, Sewanee
2005	Ryan Reynolds, Center College, KY
2005	Jackie Ryan, Davidson College, SC
2006 – 2008	Eric Lin, Stanford University, CA
2008	Elisabeth Jones, University of Kentucky, Lexington, KY
2009	Hesham Shehata, Transylvania University, KY
2009	Samantha Hargett; Asbury College, KY
2009	Colton Mojesky, Davidson College, SC
2011	Roxana Loperena (Minority Scholar), University of Puerto Rico
2012	Allyson Wollums, Asbury College, KY
2013	Johnathan Bilbro, (pre-Med) Asbury College, Wilmore, KY
2014	Lydia Livas, University of Miami, FL
2014	Tyler J. Edmonds, Asbury College, Wilmore, KY
2014	Daniel Zetter, University of Kentucky

Visiting Professorships:

June 1992	Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY
March 1995	Georgetown University Cancer Center, Washington, D.C.
June 1995	Department of Urology and the Cancer Center, University of Chicago School of Medicine, Chicago, IL
Oct. 1996	Department of Urology, Northwestern University, Chicago, IL
Feb. 1997	Department of Urology, Cornell Medical Center-New York Hospital, NY
June 1997	Brady Urologic Research Institute, Department of Urology and the Oncology Center, Johns Hopkins School of Medicine, MD

July 1998 Department of Urology, University of Tennessee, Knoxville, TN
Nov. 1999 General Post and Telecom. Hospital, Beijing, PRC
Feb. 2000 Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA
May 2000 Urology Grand Rounds, Sinai Hospital, Baltimore, MD
Oct. 2000 Department of Urology and the Prostate Cancer Program, University of Iowa, Iowa City, IA
April 2001 Department of Urology and Institute of Aging, University of Innsbruck, Innsbruck, Austria
May 2001 Urology Grand Rounds, Sinai Hospital, Baltimore, MD
May 2001 Pfizer Pharmaceuticals, Sandwich, UK
Sept. 2001 Department of Cell Biology, Georgetown University, Washington DC
Sept. 2002 Department of Anatomy, University of Turku, Turku, Finland
March 2003 Department of Cell Biology and Anatomy, Medical College of Georgia, GA
May 2003 Department of Medicinal Chemistry and Pharmacology, College of Pharmacy, Ohio State University, Columbus, OH
Oct. 2003 University of Massachusetts Medical School, Endocrinology Distinguished Lecture Series, Departments of Urology and Cell Biology, Worcester, MA
Nov. 2003 Department of Biological Sciences, University of Delaware, DE
April 2004 Northwestern University Lurie Comprehensive Cancer Center, Chicago, IL
Sept. 2004 University of Nebraska Cancer Center and Department of Biochemistry, Omaha, NE
March 2005 Department of Urology/Urologic Diseases Research Center, Children's Hospital/Harvard Medical School, Boston, MA
April 2005 Department of Urology/Cell Biology and Cancer Center, University of Minneapolis, MN
April 2005 Department of Urology, Innsbruck University/Teaching Hospital of Feldkirch, Feldkirch, Austria
April 2005 Department of Pharmacology, University College, London, England
May 2005 The Lankenau Institute for Medical Research/Thomas Jefferson University, Philadelphia, PA
Sept. 2005 Department of Pharmaceutical Sciences, University of Louisiana School of Pharmacy, Monroe, LA
Sept. 2005 Comprehensive Cancer Center, Wake Forest University, Prostate Cancer Center of Excellence Retreat, Winston-Salem, NC
Oct. 2005 Department of Urology, University of Rochester, Rochester, NY
Nov. 2005 Department of Urology and the Winship Cancer Center, Elin Lecture Series, Emory University School of Medicine, Atlanta, GA
March 2006 Department of Oncological Sciences and the Cancer Center, Mount Sinai Medical School, New York, NY
March 2006 Department of Cell Biology and Physiology, University of Miami Medical School, Miami, FL
May 2006 Department of Cell and Molecular Biology, University of Cincinnati, Cincinnati, OH
July 2006 Hematology/Oncology Grand Rounds, Cornell Medical School, New York, NY
Oct. 2006 Department of GI Oncology, M.D. Anderson Cancer Center, Houston, TX

Feb. 2007 The Prostate Centre and Department of Urology, Vancouver General Hospital, Vancouver, Canada

March 2007 The Bernadin Cancer Center, Loyola Medical Center, Chicago, IL

May 2007 Department of Urologic Oncology, Roswell Park Cancer Institute, Buffalo, NY

Nov. 2007 Department of Urology, University of Pittsburgh Medical Center, Pittsburgh, PA

Dec. 2007 Department of Urology, UT Southwestern Medical Center, Dallas, TX

Feb. 2008 Department of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan

March 2008 Medical University of Innsbruck, Department of Urology, Innsbruck, Austria

April 2008 Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA

July 2008 Purdue University, Department of Physiology and Purdue Cancer Center, West Lafayette, IN

Oct. 2008 Brown Cancer Center, University of Louisville, Louisville, KY

Oct. 2008 University of Texas M.D. Anderson Cancer Center, Department of Cancer Biology, Houston, TX

Feb. 2009 Grand Rounds Presentation, Karmanos Cancer Institute, Wayne State University, Detroit, MI

March 2009 Department of Urology Grand Rounds, Oregon Health and Sciences University, Portland, OR

March 2009 Department of Radiation Medicine, University of Oregon Health and Sciences University, Portland, OR

July 2009 Departments of Urology and Pharmacology, Weill Cornell Medical School, New York, NY

Sep. 2009 Grand Rounds, Department of Pathology and Cancer Center, University of Minnesota, Minneapolis, MN

Oct. 2009 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA

March 2010 University of Texas, MD Anderson Cancer Center, Science Park, Smithville, TX

April 2010 Stony Brook University, Dept. of Pharmacology, Stony Brook, NY

Sep. 2010 University of Colorado Cancer Center, Aurora, CO

Oct. 2010 University of California, Davis, Department of Urology and Cancer Center, Sacramento, CA

Feb. 2011 Johns Hopkins University School of Medicine, Department of Urology and Oncology Center, Baltimore, MD

March 2011 Medical University of South Carolina University, Department of Immunology and Genetics, Charleston, SC

April 2011 Vanderbilt University, Department of Cancer Biology, Nashville, TN

Dec 2011 Northwestern University, Lurie Comprehensive Cancer Center and Department of Urology, Chicago, IL

Feb. 2012 West Virginia University School of Medicine, Department of Cancer Biology and Cancer Center, Morgantown, WV

Feb. 2012 Cedars Sinai Medical Center, Urology-Oncology Program and Cancer Biology Department, Los Angeles, CA

March 2012 Cleveland Clinic, Department of Urology and Cancer Biology/Cancer Institute, Cleveland, OH

April 2012 University of Illinois at Chicago, Departments of Urology and Physiology, Chicago, IL

June 2012 Neapolis University Pafos, Academic Research Forum, Pafos, Cyprus

August 2012 Roswell Park Cancer Institute, Department of Cancer Genetics/University of Buffalo, Buffalo, NY

August 2012 University of Chicago, Departments of Surgery and Medicine, Chicago, IL

Oct. 2012 Georgia State University Dean's Distinguished Lecture, Atlanta, GA

Nov. 2012 Janssen Medical Oncology, Teleconference-Presentation on "Mechanisms of Therapeutic Resistance in Prostate Cancer Progression"

Nov. 2012 University of Michigan at Ann Arbor, Medical Grand Rounds Presentation, Comprehensive Cancer Center, Ann Arbor, MI

March 2013 University of Pittsburgh Medical Center, Department of Pathology, Pittsburgh, PA

May 2013 University of Washington School of Medicine, Department of Urology, Urology Grand Rounds, Seattle, WA

Sept. 2013 University of Minnesota Masonic Cancer Center and Hormel Institute, Minneapolis, MN

Nov. 2013 Baylor College of Medicine, Department of Biochemistry, Houston, TX

March 2014 Department of Cell Biology, Universidad Central del Caribe, Puerto Rico

April 2014 Department of Cancer Biology, University of Cincinnati, Cincinnati, OH

April 2014 Tulane University School of Medicine, Department of Structural & Cellular Biology, New Orleans, LA

Sept 2014 Department of Pharmaceutical Sciences Cancer Research Center, University of Tennessee Health Science Center, Memphis, TN

Dec 2014 Department of Biochemistry & Molecular Biology and Feist-Weiller Cancer Center LSU Health Sciences Center, Shreveport, LA

January 2015 Department of Pharmacology, University of Miami Medical School and Sylvester Comprehensive Cancer Center, Miami, FL

March 2015 Yale Comprehensive Cancer Center and Department of Urology, Yale University, New Haven, CT

March 2015 Undergraduate Research Education and Training (URGREAT) – NIH Minority Biomedical Research Support (MBRS) and Research Initiative for Scientific Enhancement (RISE), School of Science and Technology at Ana G. Mendez University System, Puerto Rico.

Invited Lectureships at National and International Conferences/Symposia:

March 1992 Annual Meeting of the Radiation Research Society, Salt Lake City, Utah

March 1993 Symposium on "Apoptosis," Joint Meeting of the German and Dutch Societies for Cell Biology, Munster, Germany

June 1994 "Apoptosis in Hormone Dependent Cancers Workshop, Berlin, Germany

July 1994 Gordon Conference in Reproductive Tract Biology. "Apoptosis in Development of Prostatic Tumors"; Plymouth State University, NH

August 1994 AUA Office of Education: Special Research Conference on Growth Factors in Urological Malignancies; Houston, TX

October 1994 10th International Endocrinology Symposium. "Molecular Biology of Apoptosis in Development, Disease and Cancer"; Lake Placid, NY

March 1995 86th Annual Meeting, American Association for Cancer Research. Session on Translational Aspects of Prostatic Cancer"; Toronto, Canada

October 1995 37th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Panel on "Late Stage, Clinically Localized Prostate Cancer"; Miami Beach, FL

November 1995 Selected Topics in Molecular Medicine: Lecture on Apoptosis, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania

December 1995 5th Fall Meeting of Society for Basic Urologic Research, Chapel Hill, NC

January 1996 Selected Topics in Molecular Biology; Lecture on Apoptosis: Incidence, Significance and Detection. Bryn Mawr College, Pennsylvania

February 1996 NIH Course; Cellular and Molecular Approaches to the Study of Cancer and Genetic Diseases, NIH, Bethesda, Maryland

November 1996 Donald Coffey Urology Research Conference, West Palm Beach, Florida

December 1996 Sixth Annual Fall Symposium of the Society for Basic Urologic Research, Asilomar State Beach, California

January 1997 NIH Course; Molecular Approaches to the Study of Cancer and Genetic Diseases: Apoptosis in Prostate Cancer, Bethesda, Maryland

March 1997 Doxazosin Investigators Educational Exchange (DICE) Meeting; Effect of Doxazosin on Prostate Proliferation/Apoptosis; San Antonio, Texas

May 1997 Seminar Speaker, American Health Foundation, Valhalla, New York

September 1997 CapCURE Fourth Scientific Retreat, Lake Tahoe, Nevada

September 1997 Cardura Study Meeting, Washington D.C.

September 1997 American Hypertension Association; Adrenoceptors in Prostate Proliferation and Apoptosis, Washington, D.C.

March 1998 Lecture Series on Molecular Approaches to the Study of Cancer; On Apoptosis in Cancer Development and Treatment, NIH, Bethesda, MD

March 1998 International Symposium on Biology of Prostate Growth, Bethesda, NIH

March 1998 XIII Congress of the European Association of Urology, Barcelona, Spain

March 1998 89th Annual Meeting of the American Association for Cancer Research, "Molecular Markers for Cancer Detection", New Orleans, LA

April 1998 International Doxazosin Exchange Meeting: Targeting Doxazosin for Prostate Cancer Therapy, Santa Fe, New Mexico

January 1999 Symposium on Diseases of the Prostate, West Palm Beach, FL

March 1999 Apoptosis Lecture in Molecular Approaches to the Study of Cancer, NIH

May 1999 Annual American Urological Association/SBUR Symposium, Dallas, TX

July 1999 Innovators in Urology Second International Conference, Oxford, UK

August 1999	Gordon Conference in Hormonal Carcinogenesis, Tilton, New Hampshire
October 1999	Prouts Neck Meeting on Prostate Cancer, NCI, Prouts Neck, Maine
November 1999	Apoptosis in BPH and Prostate Cancer; Chinese Institute of Urology, Medical University of Beijing; Beijing, PRC
January 2000	International Symposium on BPH; Prostate Apoptosis, Tokyo, Japan
February 2000	International Cardura Symposium, Canary Islands, Spain
February 2000	Eighth European Urological Winter Forum, Davos, Switzerland
February 2000	International Prostate Health Council, Antwerp, Belgium
February 2000	International Apoptosis Advisory Panel Meeting, Sintra, Portugal
April 2000	XVth Congress of the European Urological Association, Apoptosis Symposium, Brussels, Belgium
June 2000	British Association of Urologic Surgeons (BAUS) Meeting, Birmingham, UK
September 2000	Innovators in Urology Third International Meeting, Dublin, Ireland
September 2000	15 th Hellenic Urological Congress, Corfu, Greece
February 2001	International CARDURA Meeting, Puerto Rico
April 2001	International BPH Consultation Meeting, Verona, Italy
March 2002	International Symposium on Diseases of the Prostate, Seville, Spain
April 2002	International Meeting on Male Ageing, Naples, Italy
June 2002	Prostate Cancer Forum, Oxford, England
September 2002	International Society of Urology, Stockholm, Sweden
September 2002	Molecular Mechanisms as Targets of Prostatic Disease, Liverpool, UK
September 2002	International Symposium on Prostate Cancer, Baltimore, MD
November 2002	Ninth Prouts Neck Meeting on Prostate Cancer, Prouts Neck, ME
February 2003	International Cardura Conference, St. Helena, Nappa Valley, CA
July 2003	Gordon Research Conference on Hormonal Carcinogenesis, Meriden, NH
September 2003	Fifth World Congress in Urologic Research, London, UK
February 2004	Cardura International Consultation Conference, Zurich, Switzerland
November 2004	European Society of Urologic Research (ESUR) Congress, Athens, Greece
December 2004	14 th Annual Meeting of the Society for Basic Urologic Research Fall 2004, Savannah, GA
April 2005	Prostate Cancer Symposium/Impact of Prostate Cancer within the African-American Community, Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA
May 2005	Society for Urodynamics and Female Urology Meeting, San Antonio, TX
May 2005	Plenary Session Research Presentation American Urological Association Annual Meeting, San Antonio, TX
June 2005	8 th International Congress of Andrology, Seoul, Korea
December 2005	Nature/British Society of Pharmacology/SBUR Joint Symposium on Pharmacology of Urologic Diseases, Miami, FL
April 2007	American Society of Andrology Annual Meeting, Tampa, FL
September 2007	Chair, Apoptosis Symposium, IMPaCT Meeting/Department of Defense Research Programs, Atlanta, GA
September 2007	Plenary Session "Understanding the Role of Inflammation in Prostate Disease," 7 th Urologic Research Congress, Dublin, Ireland
February 2008	17 th Annual Meeting of Japanese Society for Molecular and Cellular Urology, Tokyo, Japan

April 2008 Co-Chair, AACR Annual Meeting Minisymposium, “Molecular Pathways for Sex Hormone Signaling in Breast and Prostate Cancer”, San Diego, CA

November 2008 18th Annual Meeting of the Society for Basic Urologic Research, Symposium on Novel Therapies for Prostate Cancer, Phoenix, AZ

April 2009 Moderator, Pediatrics Basic Science, American Urological Association Annual Meeting, Chicago, IL

October 2009 Prostate Cancer Symposium, New York University, New York, NY

March 2010 Prostate Cancer Symposium, Clark Atlanta University, Atlanta, GA

May 2010 Symposium on EMT in Prostate Cancer, SBUR/AUA Meeting, San Francisco, CA

May 2010 Moderator, Prostate Cancer Basic Science, Poster Discussion Session, AUA Annual Meeting, San Francisco, CA

June 2010 Speaker, Hormones and Cancer Symposium, Endocrine Society Annual Meeting, San Diego, CA

October 2010 Plenary Speaker, International Cytokine Society Meeting, Chicago, IL

October 2010 Chopin Award Recipient/Speaker, European Society for Urology Research Annual Meeting, Vilnius, Lithuania

March 2011 IMPaCT Conference, Chair and Moderator “Game Changing Research” and Experimental Therapeutics

April 2011 Speaker, Prostate Cancer Clinical Symposium, 17th Annual Oncology Meeting, Athens, Greece

May 2011 Speaker, SBUR/SUO Meeting, AUA Annual Meeting, Washington, DC

May 2011 Moderator, Poster Discussion Session, Basic Research: Prostate Cancer; AUA Annual Meeting, Washington, DC

May 2011 Prostate Cancer Symposium, Clark-Atlanta University, Atlanta, GA

September 2011 Speaker, Prostate Cancer Foundation 18th Annual Retreat, Lake Tahoe, Nevada

April 2012 Speaker, 8th Annual Kuwait Urological Association Conference, Kuwait

August 2012 Co-Chair/Moderator, American Urological Association Summer Research Conference on “Hormones and Urologic Diseases”, Baltimore, MD

November 2012 Speaker, on “Mentorship and Leadership”; 25th Fall SBUR Meeting, Miami, FL

May 2013 Moderator, Discussion Session on Prostate Cancer: Basic Research (III); 2013 Annual American Urological Association (AUA) Meeting, San Diego, CA.

June 2013 Speaker/Session Chair 1st Anticancer Research and Oncology Conference, RAHMS Meeting, Paphos, Cyprus

September 2013 Uro pathology Session Chair, 21st EAU/European Society for Urologic Research (ESUR) Meeting, Dresden, Germany

March 2014 10th Prostate Cancer Symposium, Clark Atlanta University, Atlanta, GA

March 2014 GU Research Retreat, Roswell Park Cancer Institute, Ellicott, New York.

September 2014 8th International Prostate Disease Forum, Shanghai, China

November 2014 Speaker, International Workshop in Prostate Cancer, P. Universidad Católica de Chile, Santiago, Chile

November 2014 Keynote Speaker, Symposium on Advanced Prostate Cancer, UT Southwestern Medical Center, Dallas, TX

May 2015 The 2015 Controlling Cancer Summit, London, UK

May 2015 Debate Moderator, “The Clonality of Prostate Cancer Metastasis”, Society for Urologic Oncology (SUO)/Annual AUA Meeting, New Orleans, LA

Original Manuscripts, Peer-Reviewed:

1. **Kyprianou, N.**, Williams, H., Peeling, W., Davies, P. and Griffiths, K. Evaluation of biopsy techniques for androgen receptor assay in human prostatic tissue. *Br. J. Urol.*, 58:41-44, 1986.
2. **Kyprianou, N.**, and Davies, P. Association states of androgen receptors in nuclei of human benign hypertrophic prostate. *The Prostate*, 8:363-380, 1986.
3. **Kyprianou, N.**, Gingell, C. and Davies, P. Intranuclear distribution of androgen receptors in human prostate carcinoma. *J. Endocrinol.*, 112:161-169, 1987.
4. **Kyprianou, N.**, and Isaacs, J.T. The biological significance of measurable androgen levels in the rat ventral prostate following castration. *The Prostate*, 10:313-324, 1987.
5. **Kyprianou, N.** and Isaacs, J.T. Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: Critical threshold concept. *The Prostate*, 11:41-50, 1987.
6. Isaacs, J.T. and **Kyprianou, N.** Development of androgen-independent tumor cells and their implication for the treatment of prostatic cancer. *Urol.Research*, 15:133-138, 1987.
7. Dunk, A.A., **Kyprianou, N.**, Davies, P., and Thomas, H.C. Human hepatocellular carcinoma tumor xenografts. *Digestive Diseases and Sciences*, 33(4):472-476, 1988.
8. **Kyprianou, N.** and Isaacs, J.T. Activation of programmed cell death in the rat ventral prostate following castration. *Endocrinology*, 122:552-562, 1988 (**Citation # 670**)
9. **Kyprianou, N.** and Isaacs, J.T. Identification of a cellular receptor for transforming growth factor-beta in the rat ventral prostate and its negative regulation by androgens. *Endocrinology*, 123:2124-2131, 1988.
10. **Kyprianou, N.**, English, H.F. and Isaacs, J.T. Activation of a Ca^{2+} Mg^{2+} -dependent endonuclease as an early event in castration-induced prostatic cell death. *The Prostate*, 3:103-117, 1988.
11. **Kyprianou, N.** and Isaacs, J.T. Expression of transforming growth factor- β in rat ventral prostate during castration-induced programmed cell death. *Mol. Endocrinol.*, 3:1515-1522, 1989. (**Citation # 412**)
12. **Kyprianou, N.** and Isaacs, J.T. "Thymineless" death in androgen-independent prostatic cancer cells. *Biochem. Biophys. Res. Commun.*, 165:73-81, 1989.

13. English, H.F., **Kyprianou, N.**, and Isaacs, J.T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. *The Prostate*, 15:233-250, 1989.
14. **Kyprianou, N.**, and Isaacs, J.T. Relationship between metastatic ability and ras oncogene expression in rat mammary cancer cells transfected with v-H-ras oncogene. *Cancer Res.*, 50:1449-1454, 1990.
15. **Kyprianou, N.**, English, H.F. and Isaacs, J.T. Programmed cell death during regression of the PC-82 human prostate cancer following androgen ablation. *Cancer Res.*, 50:3748-3753, 1990 (*Citation # 498*).
16. Ichikawa, T., **Kyprianou, N.**, and Isaacs, J.T. Genetic instability and the acquisition of metastatic ability by rat mammary cancer cells following v-H-ras oncogene transfection. *Cancer Res.*, 50:6349-6357, 1990.
17. Martikainen, P., **Kyprianou, N.**, and Isaacs, J.T. Effect of transforming growth factor- β on proliferation and death of rat prostatic cells. *Endocrinology*, 127:2963-2968, 1990.
18. Isaacs, W.B., Isaacs, J.T., **Kyprianou, N.**, Burgers, J.K., Alexander, R.B., Partin, A.W., Mohler, J.L., Marshall, F.F. and Coffey, D.S. New approaches to the evaluation of the metastatic ability of renal cancer and new approaches to chemotherapy. *Eur. Urol.*, 18 (Suppl.2): 33-35, 1990.
19. **Kyprianou, N.**, English, H.F., Davidson, N.E. and Isaacs, J.T. Programmed cell death during regression of MCF-7 human mammary cancer following estrogen ablation. *Cancer Res.*, 51:162-166, 1991. (*Citation # 450*)
20. **Kyprianou, N.**, Alexander, R.B. and Isaacs, J.T. Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells. *J. Natl. Cancer Inst.*, 83:346-350, 1991.
21. Martikainen, P., **Kyprianou, N.**, Tucker, R.W. and Isaacs, J.T. Programmed death of non-proliferating androgen-independent prostatic cancer cells. *Cancer Res.*, 51:4693-4700, 1991.
22. Bartek, J., Bartkova, J., **Kyprianou, N.**, Lalani, E-N., Staskova, Z., Shearer, M., Chang, S. and Taylor-Papadimitriou, J. Efficient immortalization of luminal epithelial cells from the human mammary gland by introduction of SV40 large T antigen using a recombinant retrovirus. *Proc. Natl. Acad. Sci. USA.*, 88:3520-3524, 1991.
23. **Kyprianou, N.** and Taylor-Papadimitriou, J. Isolation of azatyrosine -induced revertants from ras-transformed human mammary epithelial cells. *Oncogene*, 7:57-63, 1992.

24. Isaacs, J.T., Lundmo, P.I., Berges, R. Martikainen, P., **Kyprianou, N.**, and English, H.F. Androgen regulation of programmed death of normal and malignant prostatic cells. *Journal of Andrology*, 13: 457-464, 1992.
25. D'Souza, B., Berdichevsky, F., **Kyprianou, N.**, and Taylor-Papadimitriou, J. Collagen induced morphogenesis and expression of the alpha-2 integrin subunit is inhibited in c-erb-2 transfected human mammary epithelial cells. *Oncogene*, 8: 1797-1806, 1993.
26. Taylor-Papadimitriou, J. D'Souza, Burchell, J., **Kyprianou, N.** and Berdichevsky, F. The role of tumor-associated antigens in the biology and immunotherapy of breast cancer. *Ann. N.Y. Acad. Sci.*, 698:31-47, 1993.
27. Bova, G.S., Carter, B.S., Bussemakers, M.J.G., Emi, M., Fujiwara, Y., **Kyprianou, N.**, Jacobs, S.C., Robinson, J.C., Epstein, J.I., Walsh, P.C. and Isaacs, W.B. Homozygous deletion and recurrent allelic loss of 8p22 loci in human prostate cancer. *Cancer Res.*, 53:3869-3873, 1993. (Citation # 396).
28. Sklar, G.N., Eddy, H.A., Jacobs, S.C. and **Kyprianou, N.** Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis. *J. Urol.*, 150:1526-1532, 1993.
29. **Kyprianou, N.**, Bains, A. K. and Jacobs, S.C. Induction of apoptosis in androgen-independent human prostate cancer cells undergoing "thymineless" death. *The Prostate*, 25:66-75, 1994.
30. Burney, T.L., Rockove, S., Eiseman, J., Jacobs, S.C. and **Kyprianou, N.** Partial growth suppression of human prostate cancer cells by the Krev-1 suppressor gene. *The Prostate*, 25:176-188, 1994.
31. Tu, H., Jacobs, S.C., Mergner, W.J. and **Kyprianou, N.** Absence of human papilloma virus type 16 and 18 in primary and metastatic human prostate cancer as detected by PCR analysis. *Urology*, 44:726-731, 1994.
32. Benoit, R.M., Eiseman, J. Jacobs, S.C. and **Kyprianou, N.** Reversion of prostate tumorigenic growth by azatyrosine. *Urology*, 46: 370-377, 1995.
34. Sartor, W.M., **Kyprianou, N.**, Fabian, D. and Lefor, A.T. Enhanced expression of ICAM-1 in a murine fibrosarcoma cell line reduces tumor growth rate. *J. Surgical Res.*, 59:66-74, 1995.
35. Burno, D.K., **Kyprianou, N.**, Sartor, W.M., Fabian, D.F., Turner, J. Vu, T., Patel, A., Trimbah, C. and Lefor, A.T. Transfection of a murine fibrosarcoma with ICAM-1 enhances the response to adoptive immunotherapy. *Surgery*, 118:237-244, 1995.

36. King, E.D., Matteson, J., Jacobs, S.C. and **Kyprianou, N.** Incidence of apoptosis, cell proliferation, and bcl-2 expression in transitional cell carcinoma of the bladder: correlation with tumor progression. *J. Urol.*, 155:316-320, 1996.
37. **Kyprianou, N.**, Tu, H., and Jacobs, S.C. Apoptotic and proliferative activities in human benign prostatic hyperplasia (BPH). *Human Pathology*, 27:668-675, 1996. (**Citation # 218**)
38. Tu, H., Jacobs, S.C., Borkowski, A. and **Kyprianou, N.** Incidence of apoptosis and cell proliferation in prostate cancer: Relationship with TGF- β_1 and bcl-2 expression. *Int. Journal of Cancer*, 69: 357-363, 1996.
39. **Kyprianou, N.**, King, E.D., Bradbury, D., and Rhee, J. Bcl-2 overexpression delays radiation-induced apoptosis without affecting clonogenic survival in human prostate cancer cells. *Int. Journal of Cancer*, 70:341-348, 1997.
40. Guo.Y., Jacobs, S.C., and **Kyprianou, N.** Down-regulation of protein and mRNA expression for TGF- β_1 type I and type II receptor in human prostate cancer. *International Journal of Cancer*, 71: 573-579, 1997.
41. **Kyprianou, N.**, Bains, A.K., and Rhee, J. Transient tyrosine phosphorylation of p34^{cdc2} is an early event in radiation-induced apoptosis of human prostate cancer cells. *The Prostate*, 32: 266-271, 1997.
42. Guo, Y., Sklar, G.N., Borkowski, A., and **Kyprianou, N.** Loss of cyclin-dependent kinase inhibitor p27^{Kip1} protein expression in human prostate cancer correlates with tumor grade. *Clin. Cancer Res.*, 3: 2269-2274, 1997.
43. **Kyprianou, N.**, Allen, L.F. and Wyllie, M.G. Induction of prostate apoptosis by doxazosin: alpha-adrenoceptor-dependent and -independent actions. *Br. J. Pharmacol.*, 22:283P, 1997.
44. Guo, Y., and **Kyprianou, N.** Overexpression of transforming growth factor (TGF)- β_1 type II receptor, restores TGF- β_1 -sensitivity and signaling in human prostate cancer cells, LNCaP. *Cell Growth and Differentiation*, 9: 185-193, 1998.
45. **Kyprianou, N.**, and Rock, S. Radiation-induced apoptosis of human prostate cancer cells is independent of mutant p53 overexpression. *Anticancer Res.*, 18 (2): 897-906, 1998.
46. Berman, J., McCarthy, M. M., and **Kyprianou, N.** Effect of estrogen- withdrawal on nitric oxide synthase expression and apoptosis in the rat vagina. *Urology*, 51:650-656, 1998.
47. **Kyprianou, N.**, Litvak, J., Borkowski, A., Alexander, R.B., and Jacobs, S.C. Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia (BPH). *J. Urology*, 159:1810-1815, 1998.

48. Eiseman, J., Rogers, F., Kaufmann, J., Sentz, D., Guo, Y., Klinger, M.F., Callery, P.S. and **Kyprianou, N.** Tumor-targeted apoptosis by a novel spermine analogue, 1,12-diaziridinyl-4,9-diazadodecane, results in enhanced radiosensitivity of human prostate cancer. *Cancer Res.*, 58: 4864-4870, 1998.
49. Mackey, T., Borkowski, A., Amin, P., Jacobs, S.C. and **Kyprianou, N.** Bcl-2/ bax ratio as a predictive marker of therapeutic response to radiotherapy in prostate cancer patients. *Urology*, 52:1085-1090, 1998.
50. **Kyprianou, N.** Induction of prostate apoptosis in response to α 1-adrenoceptor antagonists: Therapeutic significance in benign prostatic hyperplasia and prostate cancer. *The Prostate Journal*, 1(2) 11-20, 1999.
51. Guo, Y., and **Kyprianou, N.** Restoration of TGF- β signaling pathway suppresses tumorigenicity of human prostate cancer cells via induction of caspase-1 mediated apoptosis. *Cancer Res.*, 59:1366-1371, 1999.
52. Chon, J.K., Isaacs, J.T., Borkowski, A., Partin, A.W., Jacobs, S.C., and **Kyprianou, N.** α 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. *Journal of Urology*, 161:2002-2008, 1999.
53. Del Pizzo, J.J., Borkowski, D., Jacobs, S.C. and **Kyprianou, N.** Loss of p27^{Kip1} and cyclin E expression correlates with tumor grade and poor survival in transitional cell carcinoma of the bladder. *Am. J. Pathol.*, 155: 1129-1136, 1999.
54. Guo, Y., Sigman, D., Borkowski, A., and **Kyprianou, N.** Racial differences in prostate cancer growth: Apoptosis and cell proliferation in African-American and Caucasian patients. *The Prostate*, 42 (2): 130-136, 2000.
55. **Kyprianou, N.** and Benning. C.M. Suppression of human prostate cancer cell growth by α 1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. *Cancer Res.*, 60:4550-4555, 2000.
56. **Kyprianou, N.**, Chon, J., and Benning, C.M. Effects of α 1-adrenoceptor antagonists on cell proliferation and apoptosis in the prostate: Therapeutic implications in prostatic disease. *The Prostate (Suppl.)*, 45(59):42-46, 2000.
57. Szostak, M., and **Kyprianou, N.** Radiation-induced apoptosis: Predictive and therapeutic significance in radiotherapy of prostate cancer. *Oncology Reports*; 7 (4): 699-706, 2000.
58. **Kyprianou, N.**, Bruckheimer, E.M. and Guo, Y. Cell Proliferation and Apoptosis in Prostate Cancer: Significance in Disease Progression and Therapy. *Histology and Histopathology*, 15: 1211-1223, 2000.

59. Glassman, D., Chon, J., Borkowski A., Jacobs, S.C. and **Kyprianou, N.** Combined effect of terazosin and finasteride on prostate apoptosis, cell proliferation and transforming growth factor- β expression in benign prostatic hyperplasia. *The Prostate*, 47:45-51, 2001.
60. Winter, R.M., Kramer, A., Borkowski A. and Kyprianou, N. Loss of caspase-1 and caspase-3 expression in human prostate cancer. *Cancer Res.*, 61: 1227-1232, 2001.
61. Szostak, M., Kaur, P., Amin, P., Jacobs, S.C. and **Kyprianou, N.** Apoptosis and Bcl-2 expression in prostate cancer: Significance in clinical outcome after brachytherapy. *Journal of Urology*, 165:2126-2130, 2001.
62. Bruckheimer, E.B., and **Kyprianou, N.** Dihydrotestosterone enhances TGF- β -induced apoptosis in hormone-sensitive prostate cancer cells. *Endocrinology*, 142:2419-2426, 2001.
63. Keledjian, K., Kim, G., Borkowski, A., Isaacs, J.T., Jacobs, S.C. and **Kyprianou, N.** Reduction of human prostate tumor vascularity by α 1-adrenoceptor antagonist, terazosin. *The Prostate*, 48:71-78, 2001.
64. Gill, J.K., Wang, L., Bretner, M., Winter, R., **Kyprianou, N.** and Hosmane, R.S. Potent in vitro anticancer activities of ring-expanded (“fat”) nucleosides containing the imidazole [4,5-E][1,3] diazepine ring system. *Nucleosides, Nucleotides and Nucleic Acids*, 20:1043-1045, 2001.
65. Anglin, I., Glassman, D.T. and **Kyprianou, N.** Induction of Prostate Apoptosis by α 1-Adrenoceptor Antagonists: Mechanistic Significance of a Quinazoline Component. *Prostate Cancer and Prostatic Diseases*. 5: 88-95, 2002.
66. Benning, C.M. and **Kyprianou, N.** Quinazoline-derived α 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an adrenoceptor-independent action. *Cancer Res.*, 62:597-603, 2002.
67. Cuellar, D., Rhee, J. and **Kyprianou, N.** α 1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction. *Anticancer Res.*, 22: 1673-1680, 2002.
68. Bruckheimer, E.M. and **Kyprianou, N.** Bcl-2 antagonizes the combined apoptotic effect of TGF- β and dihydrotestosterone in prostate cancer cells. 53:133-142, *The Prostate*, 2002.
69. Keledjian, K. and **Kyprianou, N.** Anoikis-induction by quinazoline-based α 1-adrenoceptor antagonists doxazosin and terazosin in prostate cancer cells: Antagonistic effect of bcl-2. *Jornal of Urology*, 169: 1150-1156, 2003.
70. **Kyprianou, N.** Doxazosin and terazosin suppress prostatic growth by inducing apoptosis. *Journal of Urology*, 169:1520-1529, 2003.

71. Partin, J. V., Anglin, I.E. and **Kyprianou, N.** Quinazoline-based α 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via TGF- β signaling and I κ B induction. *Brit. J. Cancer*, 88:1615-1621, 2003.
72. Zeng, L., Rowland, R., Lele, S. and **Kyprianou, N.** Apoptosis incidence and expression of p53, TGF- β RII receptor, p27^{Kip1} and Smad4 in benign, premalignant and malignant human prostate. *Human Pathol.*, 35 (3):290-297, 2004.
73. Hill, B. and **Kyprianou, N.** Effect of Permixon on prostate cancer cell growth: Lack of apoptotic action. *The Prostate*, 61 (1): 73-80, 2004.
74. Winter, R.N., Rhee, J. and **Kyprianou, N.** Caspase-1 enhances the apoptotic sensitivity of human prostate cancer cells to ionizing irradiation. *Anticancer Res.*, 24: 1377-1386, 2004.
75. Tahmatzopoulos, A. and **Kyprianou, N.** Apoptotic impact of α 1-adrenoceptor antagonists on prostate cancer growth: A myth or an inviting reality. *The Prostate*, 59:91-100, 2004.
76. Shaw, Y-J., Yang, Y-T., Garrison, J.B., **Kyprianou, N.** and Chen, C-S. Pharmacological exploitation of the alpha1 adrenoceptor antagonist doxazosin to develop a novel class of apoptosis-targeting antitumor agents that block intracellular protein kinase B/Akt activation. *J. Med. Chem.*, 47: 4453-4462, 2004.
77. Zeng, L. and **Kyprianou, N.** Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): Value in prostate cancer detection and prevention. *Prostate Cancer and Prostatic Diseases*, 8:7-13, 2005.
78. Keledjian, K., Garrison, B. J. and **Kyprianou, N.** Doxazosin inhibits vascular endothelial cell adhesion, migration and invasion. *J. Cell. Biochem.*, 94:374-388, 2005.
79. Tahmatzopoulos, A., LaGrange, A.C., Zeng, L., Mitchell, B., Conner, W. and **Kyprianou, N.** Effect of terazosin treatment on apoptosis and vascularity of bladder cancer patients. *UROLOGY*, 65:1019-1023, 2005.
80. Tahmatzopoulos, A., Sheng, S. and **Kyprianou, N.** Maspin sensitizes prostate cancer to doxazosin-induced apoptosis. *Oncogene*, 24:5375-5383, 2005.
81. Lee, Y.W., Nath, A., **Kyprianou, N.**, and Toborek, M. Human immunodeficiency virus-1 Tat protein upregulates IL-6 and IL-8 expression in human breast cancer cells. *Inflammation Res.*, 54: 380-389, 2005.
82. Rennebeck, G., Martelli, M. and **Kyprianou, N.** Anoikis and Survival Connections in the Tumor Microenvironment: Is there a Role in Prostate Cancer Metastasis. *Cancer Res.*, 65:11230-11235, 2005.

83. Garrison, J.B. and **Kyprianou, N.** Doxazosin induces anoikis of benign and malignant prostate epithelial cells via a death receptor mediated pathway. *Cancer Res.*, 66:464-472, 2006.
84. McKenzie, S. and **Kyprianou, N.** Apoptosis Evasion in Prostate Tumorigenesis: Significance in Therapeutic Resistance, *J. Cell. Biochem.*; 97:18-32, 2006.
85. Sutton, T.M., Yingling, M., Vyas, A., Atiemo, H., Borkowski, A., Jacobs, S.C. and **Kyprianou, N.** Finasteride targets prostate tissue vascularity by inhibiting cell adhesion and inducing apoptosis. *The Prostate*, 66:1194-1202, 2006.
86. Zhu, B., Fukada, K., Zhu, H. and **Kyprianou, N.** Prohibitin and Cofilin are intracellular effectors of TGF- β signaling in prostate cancer cells. *Cancer Res.*, 66:8640-8647, 2006.
87. Garcia, G.E., Arevalo, N., Gupta, A., **Kyprianou, N.**, Kumar, A.P. Akt and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract. *Neoplasia*, 8:523-533, 2006.
89. Isaacs, J., Pili, R., Qian, D., Dalrymple, S., Garrison, J., Kyprianou, N., Björk, A., Olsson, A., Leanderson, T. Identification of ABR-215050 as Lead Second Generation Quinoline-3-Carboxamide Anti-Angiogenic Agent For the Treatment of Prostate Cancer. *The Prostate*, 66(16):1768-1778, 2006.
90. Harris, A.M., Warner, B.W, Wilson, J.M., Becker, A., Rowland, R.G., Conner, W., Lane, M., Kimbler, K., Durbin, E.B., Baron, A.T. and **Kyprianou, N.** Effect of α 1-Adrenoceptor Antagonist Exposure on Prostate Cancer Incidence: An Observational Cohort Study. *J. Urology*; 178:2176-2180, 2007.
91. Garrison, J.B., Shaw, Y-J., Chen, C-S. and **Kyprianou, N.** Novel Quinazoline-based Compounds Impair Prostate Tumorigenesis by Targeting Tumor Vascularity, *Cancer Res.*, 67(23):11344-11352, 2007.
92. Zhu, M., Partin, J.V., Bruckheimer, E.M., Strup S.E. and **Kyprianou, N.** TGF- β signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells. *The Prostate*, 68(3):287-295, 2008.
93. Sakamoto, S., Ryan, A.J. and **Kyprianou, N.** Targeting Vasculature in Urologic Tumors: Current Therapeutic Value, *J. Cell. Biochem*, 103(3):691-708, 2008.
94. Martin, F.M., Harris, A.M., Rowland, R.G., Conner, W., Lane, M., Durbin, E., Baron, A.T. and **Kyprianou, N.** Decreased Risk of Bladder Cancer in Men Treated with Quinazoline-Based α 1-Adrenoceptor Antagonists. *Gene Therapy & Molecular Biology*, 12(B):253-258, 2008.
95. Schwarze, S.R., Lin, E.W., Christian, P.A., Gayheart, D.T. and **Kyprianou, N.** Intracellular Death Platform Steps-In: Targeting Prostate Tumors via Endoplasmic Reticulum (ER) Apoptosis. *The Prostate*, 68:1615-1623, 2008.

96. McKenzie, S., Sakamoto, S., and **Kyprianou, N.** Maspin sensitizes apoptotic response of prostate cancer cells to hypoxia. *Oncogene*, 27:7171-7179, 2008.
97. Zhu, M.L., and **Kyprianou, N.** Androgen Receptor and Growth Factor Signaling Partnerships in Prostate Cancer Cells. *Endocrine Related Cancer*, 15:841-849, 2008.
98. Srinivasan S, Koduru S, Kumar R, Venguswamy G, **Kyprianou N**, Damodaran C. Diosgenin Targets Akt-mediated Pro-survival Signaling in Human Breast Cancer Cells. *Int J Cancer*, 11;125(4):961-967, 2009.
99. Pu, H., Collazo, J., Jones, E., Gayheart, D., Sakamoto, S., Vogt, A., Mitchell, B., and **Kyprianou, N.** Dysfunctional TGF- β Receptor II Accelerates Prostate Tumorigenesis in the TRAMP Mouse Model. *Cancer Res.*, 69(18):7366-7374, 2009.
100. Zhu, B., Zhai, J., Zhu, H., and **Kyprianou, N.** Prohibitin Regulates TGF- β Induced Apoptosis as a Downstream Effector of Smad-dependent and -independent Signaling. *The Prostate*, 70(1):17-26, 2010.
101. Zhu, M. and **Kyprianou, N.** Role of Androgens and the Androgen Receptor in Epithelial-Mesenchymal Transition and Invasion of Prostate Cancer Cells. *The FASEB Journal*, 24(3):769-777, 2010 (**Citation # 83**)
102. Sakamoto, S., McCann R.O., Dhir, R. and **Kyprianou, N.** Talin1 Promotes Tumor Invasion and Metastasis via Focal Adhesion Signaling and Anoikis Resistance. *Cancer Res.*, 70(5):1885-1895, 2010 (**Citation # 81**)
103. Zhu, M., Horbinski, C., Garzotto, M., Qian D., Beer, T. and **Kyprianou, N.** Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. *Cancer Res.*, 70(20):7992-8002, 2010. (**Citation #115**)
104. Horbinski, C., Mojesky, C. and **Kyprianou, N.** Live Free or Die: Tales of Homeless Cells in Cancer. *Am. J. Pathol.*, 177(3):1044-52, 2010.
105. Wang, Wang-Xia, **Kyprianou, N.** and Nelson, P. M. Dysregulation of the mitogen granulin in human cancer through the miR-15/107 microRNA gene family. *Cancer Res.*, 70(22):9137-9142, 2010.
106. Sakamoto, S., Schwarze, S., and **Kyprianou, N.** Anoikis Disruption of Focal Adhesion-Akt Signaling Impairs Renal Cell Carcinoma. *European Urology*, 59(5):734-744, 2011.
107. Zhu, H., Zhao, J., Zhu, B., Collazo, J., Gal, J., Shi, P., Liu, L., Strom, A.L., Lu, X., McCann, R.O., Toborek, M., and **Kyprianou, N.** EMMPRIN Regulates Cytoskeleton Reorganization and Prostate Cancer Cell Invasion, *The Prostate*, 72(1):72-81, 2012.
108. Fiandalo, M., Schwarze, S. R. and **Kyprianou, N.** Regulation of caspase-8 activity by proteosomal degradation in cancer cells. *APOPTOSIS*, 18:766-776, 2013.

109. Gilbert, M., Liu, J., Neltner, J., Pu, P. Morris, A., Sunkara, M., Pittman, T., **Kyprianou, N.** and Horbinski, C. Autophagy and oxidative stress in gliomas with IDH1 mutations. *Acta Neuropathol.*, 127(2):221-233, 2014.
110. Collazo, J., Zhu, B., Larkin, S., Pu, H., Koochekpour, S., Martin, S.K, Horbinski, C. and **Kyprianou, N.** Cofilin regulates cellular invasion responses to TGF- β towards prostate cancer metastasis. *Cancer Res.* 74(8):2362-2373, 2014.
111. Hensley, P., Desiniotis A., M., Wang, C., Stromberg A., Chen, C-S and **Kyprianou, N.** Novel pharmacologic targeting of tight junctions in prostate cancer cells. *PLOS ONE*, 9(1):e86238, 2014.
112. Pu, H., Horbinski, C., Hensley, P., Matuszak, E.A, Atkinson, T. and **Kyprianou, N.** Poly (ADP) ribose polymerase-1 (PARP-1) regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis. *Carcinogenesis*, 35(11):2592-601, 2014.
113. Liu Y, Gilbert MR, **Kyprianou N**, Rangnekar VM, Horbinski C. The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. *Acta Neuropathol.* , 2014.
114. Martin, S. K., Banuelos, C.A., Sadar, M. D. and **Kyprianou, N.** N-Terminal Targeting of Androgen Receptor Variant Enhances Therapeutic Response of Castration-resistant Prostate Cancer to Taxanes. *Molecular Oncology*,: S1574-7891(14)00263-4, 2014.
115. Pu, H., Cao, Z., Edmonds, T.J., Horbinski, C., and **Kyprianou, N.** Androgen axis dictates TGF- β mediated epithelial mesenchymal transition (EMT) during prostate tumorigenesis. *Manuscript submitted for publication*, 2014.
116. Martin, S.K., Pu, H., Cao, Z. Horbinski, C. Strup, S.E. and **Kyprianou, N.** Targeting mechanisms of resistance to Cabazitaxel in advanced metastatic prostate cancer. *Manuscript in preparation*, 2014.

Review Articles (Peer-Reviewed):

1. **Kyprianou, N.** Apoptosis: Therapeutic significance in the treatment of androgen dependent and independent prostate cancer. *World J. Urology*, 12:299-303, 1994.
2. Bruckheimer, E. M. and **Kyprianou, N.** Apoptosis in Prostate Carcinogenesis: A Growth Regulator and a Therapeutic Target: A Review. *Cell and Tissue Research Special Issue on Apoptosis*, 301:153-162, Springer-Verlag, 2000.
3. Cuellar, D. and **Kyprianou, N.** Recent Advances in Medical Therapy of Benign Prostatic Hyperplasia (Review) in *Current Urology Reports* (Ed., B. Djovan). 11:27-33, 2001.

4. Hill, B., and Kyprianou, N. Sequencing Hormonal Therapy and Radiotherapy in Prostate Cancer: A Molecular and Therapeutic Perspective. *Oncology Reports*, 9:1151-1156, 2002.
5. Garrison, J.B. and **Kyprianou, N.** “Novel Targeting of Anoikis for Prostate Cancer Therapy” *Current Cancer Drug Targets; (Cancer Therapeutics)*, 4:85-95, 2004.
6. Tahmatzopoulos, A, Rowland, R.G. and **Kyprianou, N.** “The Role of Alpha Blockers in the Management of Prostate Cancer” in *Expert Opinion on Pharmacotherapy*; 5: 1279-1285, 2004.
7. Zhu, B. and **Kyprianou, N.** TGF- β Signaling in Prostate Cancer. *Cancer Treat. Res.*, 126:157-173, 2005.
8. Reynolds, R.A. and **Kyprianou, N.** Growth Factor Signaling in Prostatic Growth: Significance in Tumour Development and Therapeutic Targeting. *British Journal of Pharmacology*, 147:S144-S152, 2006.
9. Jones, E., Pu, H. and **Kyprianou, N.** Targeting TGF- β in Prostate Cancer: Therapeutic Possibilities during Tumor Progression. *Expert Opinion in Therapeutic Targets*, 13(2): 227-234, 2009.
10. **Kyprianou, N.**, Vaughan, T. and Michel M.C. Apoptosis induction by doxazosin and other quinazoline adrenoceptor antagonists: a new mechanism for cancer treatment? *Naunyn-Schmied Arch Pharmacol*, 380(6):473-477, 2009.
11. Sakamoto S. and **Kyprianou, N.** Targeting Anoikis Resistance in Prostate Cancer Metastasis. *J. Molecular Aspects of Medicine; Special issue on Molecular Mechanisms and New Therapeutic Targets in Human Carcinogenesis*; 31(2):205-214, 2010.
12. Matuszak, E. and **Kyprianou, N.** Androgen Regulation of Epithelial-Mesenchymal Transition in Prostate Tumorigenesis. *Expert Reviews in J. Clinical Endocrinology and Metabolism*, 6(3):469-482, 2011.
13. Desiniotis, A. and **Kyprianou, N.** Significance of Talin in Cancer Progression and Metastasis, *International Review of Cell and Molecular Biology*, Elsevier, 2011; Ch. 4, Volume 289, pp.117-147.
14. Desiniotis, A. and **Kyprianou, N.** Advances in the Design and Synthesis of Prazosin Derivatives over the Last Ten Years. *Expert Opinion in Therapeutic Targets*, 15(12):1405-1418, 2011.
15. Hensley, J.P. and **Kyprianou, N.** Modeling prostate cancer in mice: Opportunities and Limitations. *J. Andrology*, 33(2):133-144, 2012.

16. Martin, S.K., Vaughan, T.B., Atkinson, T., Zhu, H. and **Kyprianou, N.** Prostate Cancer Biomarker Update. *Oncology Reports*, 28: 409-417, 2012.
17. Fiandalo, M.V. and **Kyprianou, N.** Caspase Control: Protagonists of Cancer Cell Apoptosis in *Experimental Oncology*; Special issue on "Apoptosis: four decades later", 34(3):165-175, 2012.
18. Hensley, J.P., Mishra, M. and **Kyprianou, N.** Targeting Caspases in Cancer Therapeutics; *Biological Chemistry*, 394(7):831-843, 2013.
19. Hendrix, L.N., Hamilton, A.D. and **Kyprianou, N.** Emerging therapeutics targeting castration resistant prostate cancer: the AR-mageddon of tumor epithelial-mesenchymal transition. *Expert Reviews of Endocrinology and Metabolism*, 8 (4): 403-416, 2013.
20. Larkin, S. and **Kyprianou, N.** Molecular Signatures in Urologic Tumors in "Molecular Research in Urology" *Int J Mol Sci.* 6,14(9):18421-18436, 2013.
21. Bilbro, J.M. Mart, M. and **Kyprianou, N.** Therapeutic Value Novel Quinazoline-Based Compounds in Prostate Cancer. *Anticancer Research*, 33 (11):4695-4700, 2013.
22. Grant, C. and **Kyprianou, N.** Epithelial-mesenchymal-transition (EMT) in prostate growth and tumorigenic development. *Translational Urology and Andrology*, 2(3):202-211, 2013.
23. Khan, B., Collazo, K. and Kyprianou, N. Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer. *Int J Biol Sci.* 1;10(6):588-595, 2014.
24. Lacy, J. and **Kyprianou, N.** A Tale of Two Trials: Impact of 5 α -reductase Inhibition on Prostate Cancer. *Oncology Letters*, 8(4):1391-1396, 2014.
25. Martin, S.K., Kamelgran, M., and **Kyprianou, N.** The Cytoskeleton Targeting Value in Prostate Cancer Treatment. *Am. J. of Clinical and Exper. Urol*, 2(1):15-26, 2014.
26. Cao, Z. and **Kyprianou, N.** Mechanisms Navigating TGF- β Signaling in Advanced Prostate Cancer. Review, *Asian Journal of Urology*, 1: 48-55, 2014.
27. Miremami, J. and **Kyprianou, N.** Novel Bladder Cancer Markers: Promise and Validation in 2014, Review; *Int. J. Mol. Sci., in press*, 2014.
28. Stark. T., Livas, L., Pu, H. and **Kyprianou, N.** Inflammation in Prostate Cancer Progression and Targeting. *Translational Urology and Andrology*, submitted for publication, 2014.

Books/Monographs:

Kyprianou, Natasha, MOLECULAR EXPLOITATION OF APOPTOSIS PATHWAYS IN PROSTATE CANCER, *Monograph*, Molecular Medicine and Medicinal Chemistry Series, Imperial College Press, London, April 2012, United Kingdom.

Book Chapters:

1. Isaacs, J.T. and **Kyprianou, N.** Biological basis for combined chemohormonal therapy for prostatic cancer. In *New Trends in Diagnosis and Treatment of Prostatic Cancer*. Acta Medica Edizioni Congress, pp. 241-255, 1987.
2. Isaacs, J.T., Schulze, H. and **Kyprianou, N.** Experimental studies on the optimal therapy for prostatic cancer. In *The Prostate* (Fitzpatrick and Krane, Eds.), Churchill Livingstone, London, pp. 33-40, 1989.
3. Isaacs, J.T. and **Kyprianou, N.** Biological basis for chemohormonal therapy for prostatic cancer. In *Urologic Oncology* (Lepor, H. and Ratliff, T.L., Eds.), Kluwer Academic Publishers, Boston, pp. 177-193, 1989.
4. **Kyprianou, N.**, Martikainen, P. and Isaacs J.T. Programmed cell death of normal and malignant prostatic cells. In *Endocrine Dependent Tumors* (Voigt, K-D. and Knabbe, C., Eds), Raven Press Ltd, New York, pp. 69-81, 1991.
5. **Kyprianou, N.**, Bartek, J. and Taylor-Papadimitriou, J. Effects of v-H-ras oncogene on immortalized non-tumorigenic human mammary epithelial cells. In *The Superfamily of Ras-related Genes* (Spandidos, D.A., ed.). NATO ASI Series, Plenum Press, New York, pp. 317-326, 1991.
6. **Kyprianou, N.**, Martikainen, P., Davis, L., English, H.F. and Isaacs, J.T. Programmed Cell Death as a New Target for Prostatic Cancer Therapy. *Cancer Surveys*, Vol. 11: Prostate Cancer, pp. 265-277, Imperial Cancer Research, 1991.
7. **Kyprianou, N.** Therapeutic Significance of Apoptosis in the Treatment of Prostate Cancer. In: "Apoptosis in Hormone Dependent Cancers" *Schering Research Foundation*, (Eds) Michna H & Tenniswood M. Springer-Verlag, Berlin, New York, pp. 57-69, 1994.
8. **Kyprianou, N.** Role of Apoptosis in Development of Benign Prostatic Hyperplasia (BPH) and Prostatic Cancer: Clinical Significance in Diagnosis and Treatment. In *Prostate: Basic and Clinical Aspects*; Naz. R. (Ed.), CRC Press, pp. 181-199, 1997.
9. **Kyprianou, N.** Tissue proliferation and apoptosis: differential effects of alpha-adrenoceptor antagonists. In *Textbook of Benign Prostatic Hyperplasia* (eds. Kirby, R.S., McConnell, J.D., Fitzpatrick, J.M., Boyle, P., Wyllie, M.G.) (1st edition), Isis Medical Media Ltd., Oxford, Chapter 36, pp. 13-18, 2000.
10. Bruckheimer, E.M. and **Kyprianou, N.** Apoptosis and Cell Cycle Deregulation in Prostate Cancer *in Prostate Cancer: Scientific and Clinical Aspects-Bridging the Gap*; (El-Lalani, N. and Abel, P.; eds), Imperial College Press, London, 2003, pp. 511-549.

11. **Kyprianou, N.** The Differential Effects of Adrenoceptor Antagonists on Prostate Tissue Growth. In Textbook of Benign Prostatic Hyperplasia; Chapter 26; Eds. Kirby, R., McConnell, JD, Fitzpatrick, JM, Roehrborn, CG and Boyle, P. (2nd edition) Taylor and Francis Group, Abingdon, Oxon, UK. FL. pp. 351-356, 2005.
12. Zhu, B. and **Kyprianou, N.** "TGF- β and Prostate Cancer" in *Cytokines and Cancer* (editor, Plataniias, L); Kluwer Academic Publishers; 2005, pp. 157-173.
13. Bylund, J. Tahmatzopoulos, A. and **Kyprianou, N.** Growth Factor Signaling Pathways Regulating Prostate Growth in "Prostate Cancer: Principles and Practice" (Editors, Partin, A. Kirby, R., et al) 2006, Taylor and Francis, Oxford, pp. 91-101.
14. Zhu, B. and **Kyprianou, N.** Transforming growth factor- β and cancer; in the "Molecular and Cellular Basis of Cancer"; The Cancer Textbook, (Editor, Alison, M.R.) 2007, Ch. 22, pp. 257-271.
15. Collazo, J. and **Kyprianou, N.** Transforming Growth Factor- β (TGF- β) Signaling Dictates Apoptotic and Angiogenic Response in Prostate Cancer, in "Angiogenesis and Therapeutic Targets in Cancer (Editor, Prof. Chatterjee, Malay); 2010; pp. 354-368.
16. Tang, X., Tang, X., Gal, J., **Kyprianou, N.**, Zhu, H. and Tang, G. Detection of microRNAs in prostate cancer cells by microRNA array. *Methods in Molecular Biology: MicroRNAs in Development*, 2011, 732:69-88.
17. Martin, S.M., Fiandalo, M.V. and **Kyprianou, N.** Androgen Receptor Signaling Interactions Control Epithelial-mesenchymal Transition of Prostate Cancer Progression; in "Androgen-Responsive Genes in Prostate Cancer: Regulation, Function and Clinical Applications"; (Ed. Wang, Z.) Springer Science, 2013, pp.227-255.

Commentaries and Editorials:

1. **Kyprianou, N.** Doxazosin research offers hope for combination BPH therapy. *Urology Times*, 25, (6), June issue, p.17, 1997.
2. **Kyprianou, N.** Spermine analogue doubles prostate cancer cells' radiation sensitivity by increasing apoptosis rate: New hope for prostate cancer therapy. *Urology Times*, 25 (11), December issue, p.25, 1997.
3. **Kyprianou, N.** and Mackey, T.M. High bcl-2/bax ratio points to greater risk of prostate cancer radiation failure. *Urology Times*, October, p.2, 1998.
4. **Kyprianou, N.** Induction of prostate apoptosis in response to Terazosin and Doxazosin in benign prostatic hyperplasia and prostate cancer. *Urology Times*, Vol. 27 (2), June 1999.

5. **Kyprianou, N.** Activation of TGF- β signaling in human prostate cancer cells suppresses tumorigenicity via deregulation of cell cycle progression and induction of caspase-1 mediated apoptosis: Significance in prostate tumorigenesis. *Prostate Cancer and Prostatic Diseases*, Vol. 2 (Suppl. 3); November 1999.
6. **Kyprianou, N.** Induction of apoptosis by α 1-adrenoceptor antagonists in benign prostatic hyperplasia and prostate cancer. *Prostate Cancer and Prostatic Diseases*, Vol. 3 (Suppl. 1); S24-S25, December 2000.
7. **Kyprianou, N.** Apoptosis is the theme of the Society for Basic Urologic Research (SBUR) Spring 2004 meeting, *AUA News*, March/April 2004.
8. **Kyprianou, N.** Translational Research in Urology-Are We There Yet? *AUA News*, September 2007.
9. **Kyprianou, N.** TGF- β signaling dictates therapeutic targeting in prostate cancer, *Therapy*, 5(1):7-11, 2008.
10. **Kyprianou, N.** Autophagy – Can Self-Cannibalism Find a Place in Urological Disease? *AUA News*, p. 12, May, 2008.
11. **Kyprianou, N.** Editorial Comment on “A duplex qPCR assay based on quantification of methylacyl-CoA racenase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer.” *J. Urol.*, 181: 2513-2514, 2009.
12. **Kyprianou, N.** ASK-ing EMT not to spread cancer. *PNAS*, 107(7):2731-2732, 2010.
13. Martin, S.K. and **Kyprianou, N.** Gene fusions find an ERG-way to tumor inflammation. *Cancer Biology & Therapy*, Commentary; 11(4):418-420, 2011.
14. Matuszak, E.M. and **Kyprianou, N.** Expression Patterns of EMT Markers in Localized Prostate Cancer: Significance in Clinicopathological Outcomes following Radical Prostatectomy. *British J. Urology International*, Commentary; 111(1):6-7, 2013.
15. Fiandalo, M.V. and **Kyprianou, N.** p27 Stands-Up-To-Cancer: UPS Nuclear Service Stops. News and Views, *Endocrinology*, 154(11):3970-3973, 2013.
16. **Kyprianou, N.** The Fringe Benefits of Cloning Cancer. Focus Article, *Science Transl Med.* Sep 17;6(254):254fs36, 2014.

Broadcasting:

Center for Cancer Research and Therapeutic Development (CCRTD) at Clark Atlanta University; Monthly radio program, “Men’s Health Line with Dr. Bennett” on WCLK 91.9 FM. Live: Prostate Cancer 101. Wednesday, **January 19, 2011.**

Center for Cancer Research and Therapeutic Development (CCRTD) at Clark Atlanta University; Monthly radio program, “Men’s Health Line with Dr. Bennett” on WCLK 91.9 FM. Live: Prostate Cancer 101. Wed, **April 18, 2012.**

Radio Paphos, Cyprus, Morning Radio Program, Live Interview/Discussion with reporter, Panicos Evrypidou, on Prostate Cancer Therapeutic and Prevention Strategies. “Increasing Cancer Awareness” Wed, **June 20, 2012.**

Sigma TV-Magazino, Live Program, Interview on the Cancer Epidemic in Cyprus, Taking Questions from Viewers, Nicosia, Cyprus, **April 22, 2013.**

Radio Paphos, Morning Radio Program, Live Interview on 1st International Anticancer Research and Oncology Conference in Paphos, Cyprus, **June 6, 2013.**

Book Reviews:

Denis, L.J., Behre, H.E., Griffiths, K., Krieg, M., **Kyprianou, N.**, Lee, C., Mahler, C.H., Pertisch, P., Prezioso, D., Prins, G.S., Tunn, U. and Vermeulen, A. Oestrogens and Prostatic Disease. Proceedings of an IHPC Group; *The Prostate*, 2000.

Kyprianou, N. and Jacobs, S.C. Apoptosis Induced by Alpha Blockers in the Prostate: A Novel Effect of “Old Drugs”, (Review) *in* Current Urology Reports (eds., J. Fitzpatrick and S.Kaplan). Vol. 1 (2):89-96, 2000.

Kyprianou, N. The induction of prostate apoptosis by alpha blockers. Web Teaching Course; Italian Program; 2003.

Manuscripts in Preparation:

1. Yang, L., Ravindranath, P., Collazo, C., Fazli, L., Li, E. He, D., Tilley, W.D., Hsieh, J.T, So, A., **Kyprianou, N.** and Raj, G.V. Androgen deprivation therapy targets epithelial-mesenchymal-transition (EMT) in prostate cancer. *Manuscript in preparation*; 2015.

Last revised 12/10/2014